Discovering genetic drivers in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by Huang, Hu
DISCOVERING GENETIC DRIVERS IN ACUTE 
GRAFT-VERSUS-HOST DISEASE AFTER 
ALLOGENEIC HEMATOPOIETIC STEM CELL 
TRANSPLANTATION 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF  
THE UNIVERSITY OF MINNESOTA 
BY 
 
 
  
 
HU HUANG 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
ADVISORS: 
 
CALEB KENNEDY, PH.D. 
CLAUDIA NEUHAUSER, PH.D. 
 
 
 
 
MAY, 2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright 2019 by Hu Huang  
All Rights Reserved 
 
 i 
Acknowledgements 
Completion of a Ph.D. requires one's motivation, dedication, and determination. More 
importantly, it needs a network of support and guidance from academics, mentors, 
family, and friends. During the past six years, I was lucky enough to have such a 
fantastic and generous group of people. 
 
First and foremost, I am deeply indebted to my academic advisor Dr. Claudia Neuhauser 
for all the intellectual and emotional support, and encouragement she gave me since the 
beginning of my graduate study, especially during the tough times in the Ph.D. pursuit. 
Without her guidance and motivation, it would not have been possible to achieve what I 
accomplished today.  
 
I would also like to extend my deepest gratitude to my research advisor, Dr. Caleb 
Kennedy. The last four years at the National Marrow Donor Program (NMDP) has been 
a fantastic experience, and I thank Dr. Kennedy wholeheartedly, not only for his 
tremendous academic support but also for his continuous encouragement, profound 
belief in my abilities and giving me the freedom to explore many creative ideas.  
 
Special thanks go to Dr. Hongbo Xie at the Queensland University of Technology 
(formerly at Jiangsu University), who encouraged me to embark on the path of machine 
learning applications in biomedical science and engineering research, and provided me 
 ii 
with a fantastic training in scientific research and writing. My intellectual pursuits and 
American dream were largely inspired by him. 
 
I would like to express my most profound appreciation to my preliminary and final exam 
committee, Dr. Abeery Madbouly, and Dr. Chad Myers, for their time, interest, helpful 
comments, and productive discussions. I gratefully acknowledge the assistance of Dr. 
Madbouly from the Center for International Blood and Marrow Transplant Research 
(CIBMTR) throughout my research at NMDP.  
 
The members of the NMDP Bioinformatics Research Group and CIBMTR have 
contributed immensely to my personal and professional growth during the past four 
years. Special thanks to Wei Wang, Michael Halagan, Jason Brelsford, Pradeep 
Bashyal, Stephanie Fingerson, Julia Udell, Stephen Spellman, Cynthia Vierra-Green, 
Colleen Brady, Jane Pollack, Debra Turner, and Jayesh Iyer, for their technical support, 
challenging discussions, valuable advice and collaboration, and great friendships.    
 
I gratefully acknowledge the funding sources that made my Ph.D. work possible. The 
University of Minnesota, Bioinformatics and Computational Biology (BICB) Program 
provided Graduate Fellowship for my first year and the NMDP/CIBMTR and BICB 
program funded the rest of my Ph.D. research. 
 
My time at the University of Minnesota, Twin Cities was made colorful and enjoyable 
thanks to the many friends who came into my life. I am grateful to Praveen Kumar and 
Madhu Kumari for making stressful times fun, comforting and memorable. To Dr. Pajau 
 iii 
Vangay for academic and emotional support whenever I needed the most. To my old 
roommate Dr. Youssef Roman, for the inspiring stories and motivational conversations. 
To Jeremy Dowd for introducing me to the local communities through volunteering 
opportunities, especially connecting with the GLBTQ community. Those were the 
precious memories and experiences that made my graduate life in Twin Cities extremely 
special.  
 
Lastly, I would like to thank my parents who raised me with grit and supported me in all 
my academic pursuits. Without their relentless support, I would not have been able to 
fulfill my dream. And most of all, for my loving, supportive, encouraging, and patient 
fiancé, Tom, who made the stressful graduate life fun and exciting with amazing National 
Parks adventures. His unwavering support during the final stages of this Ph.D. is so 
much appreciated.  
 
It has been a marvelous ride!  
 
Hu Huang 
University of Minnesota, Twin Cities 
May 2019 
 
 
  
 
 iv 
Dedication 
 
 
To my love, Tom, 
who made this journey extra special and exciting! 
 
 v 
Abstract 
Acute graft-versus-host disease (GVHD) is one of the major complications after 
allogeneic hematopoietic stem cell transplantation (allo-HCT) that cause non-relapse 
morbidity and mortality. Although the increasing matching rate of the human leukocyte 
antigen (HLA) genes between donor and recipient (DR) has significantly reduced the risk 
of GVHD, clinically significant GVHD remains as a transplantation challenge, even in 
HLA-identical transplants. Candidate gene studies and genome-wide association studies 
have revealed susceptible individual genes and gene pairs from DR pairs that are 
associated with acute GVHD; however, the roles of genetic disparities between donor 
and recipient remain to be understood. 
  
To identify genetic factors linked to acute GVHD, we investigated the classical HLA and 
non-HLA genes and conducted a genome-wide clinical outcome association study. 
Assessment of 4,646 antigen recognition domain (ARD)-matched unrelated donor allo-
HCT cases showed that the frequency of mismatches outside the ARD in HLA genes is 
very low when the DR pairs are matched at ARD. Due to the low frequency of amino 
acid mismatches in the non-ARD region and their reportedly weak alloimmune reactions, 
we suggest that the non-ARD sequence mismatches within the ARD-matched DR pairs 
have limited influence on the development of acute GVHD, and may not be a primary 
factor. The genome-wide clinical outcome association study between DR pairs observed 
multiple autosomal minor histocompatibility antigens (MiHAs) restricted by HLA typing, 
though their association with acute GVHD outcome was not statistically significant. This 
 vi 
result suggests that HLA mismatching outweighs other genetic mismatches as 
contributors to acute GVHD risk. In the cases of female donors to male recipients, we 
identified the significant association of the Y chromosome-specific peptides encoded by 
PCDH11Y, USP9Y, UTY, and NLGN4Y with the acute GVHD outcome. 
  
Additionally, we developed a machine learning-based genetic variant selection algorithm 
for ultra-high dimensional transplant genomic studies. The algorithm successfully 
selected a set of genes from over 1 M genetic variants, all of which have evidence to be 
linked to the transplant-related complications. 
  
This work offers evidence and guidance for further research in acute GVHD and allo-
HCT and provides useful bioinformatics and data mining tools for transplant genomic 
studies. 
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Chapter 1 Introduction 
 
Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been widely used as a 
curative treatment for a series of hematologic malignancies and inherited genetic 
diseases. Bone marrow is an organ that is rich in hematopoietic stem cells (HSCs) and 
was used as the primary source of donor stem cells in allo-HCT until the early 2000s 
(Griffioen, van Bergen, and Falkenburg 2016). Peripheral blood-derived stem cells 
(PBSCs) have become a popular alternative of HSCs since its first published report 
(Goldman et al. 1978). Especially in the autologous setting, PBSCs are preferred over 
bone marrow due to ease of collection and quick engraftments (Cutler and Antin 2001). 
Although PBSCs were more cautiously monitored in allo-HCTs, the number of allogeneic 
PBSC transplant cases has increased dramatically since the report of mobilized PBSCs 
through Granulocyte colony-stimulating factor (G-CSF) or Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Schmitz et al. 1995; Welniak, Blazar, and Murphy 
2007) and the reports of the similar transplant outcomes using PBSCs to that of bone 
marrow stem cells. The use of PBSCs in allo-HCT exceeded that of the allo-HCT cases 
with bone marrow stem cells since 2014 (D’Souza and Zhu 2017). Another rich source of 
HSCs is umbilical cord blood (UCB), which has gained popularity as an attractive graft 
source (Benito et al. 2004; Sullivan 2008). UCB derived HSCs are immunologically 
naive, resulting in attenuated donor-derived immune response compared to bone 
marrow stem cells (Sullivan 2008). Multiple retrospective studies have suggested that 
transplant cases that use UCB-derived stem cells yield similar transplant outcomes to 
that of the bone marrow transplant cases, supporting a broader applications of UCB 
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stem cells and the promotion of cord blood banking (Eapen et al. 2007; Barker and 
Wagner 2003; Hwang et al. 2007; Ballen, Gluckman, and Broxmeyer 2013; Lou, Zhao, 
and Chen 2018).  
 
The most crucial criterion in allo-HCT is to identify the tissue compatibilities through the 
major histocompatibility complex (MHC) between a potential donor and the recipient to 
avoid graft rejection. More specifically, an ideal graft source would have identical human 
leukocyte antigen (HLA) genes as the recipient. The HLA gene system is one of the 
most extensively studied human gene regions due to its high polymorphism (Robinson et 
al. 2015; Gourraud et al. 2014; Horton et al. 2004; Xie et al. 2003) and its critical role in 
allogeneic solid organ transplant (liver, kidney etc.) and allo-HCT (Petersdorf 2013). The 
HLA region has also been used extensively to study  population diversity (Sanchez-
Mazas and Meyer 2014), the evolutionary history of human ancestry (Gourraud et al. 
2014; Uinuk-Ool, Takezaki, and Klein 2003), the association with multiple 
immunodeficiency diseases, such as HIV/AIDS (Goulder and Walker 2012), and other 
genetic diseases and cancer (Horton et al. 2004; de Bakker et al. 2006; Shiina et al. 
2009).  
 
One of the main transplant-related complications after HLA matching allo-HCT is called 
graft-versus-host disease (GVHD), which is caused by the graft immune cells (mainly T 
cells) that recognize peptides from the host as non-self antigens. This recognition 
initiates a chain of immune reactions and the cells in the recipient are attacked. These 
peptides are called the minor histocompatibility antigens (MiHAs) in distinction to the 
major histocompatibility complex (MHC) that leads to graft rejection. When the graft T  
 3 
 
Figure 1.1 Illustration of genomic position of classical HLA genes and classical MHC molecules. 
The MHC molecule artwork is adapted from https://microbeonline.com/difference-mhc-class-mhc-
class-ii-proteins/. (a) Genomic position of HLA genes on chromosome 6, (b) HLA class I genes 
functional composition and the corresponding MHC class I molecule, and (c) HLA class II genes 
functional composition and the corresponding MHC class II molecule. Blue dotted arrows indicate 
the corresponding exon regions and the encoded antigen recognition domains (ARDs). Exons 2 
and 3 in HLA class I genes and Exon 2 in HLA class II genes encode the ARD, respectively. 
cells recognize MiHAs in the tumor cells, it leads to graft-versus-leukemia (GVL) effect, 
which is beneficial to disease remission. Graft selection in allo-HCT is to minimize the 
GVHD while maximizing GVL effect.  
 
The human leukocyte antigen (HLA) gene system 
The HLA genes are located on chromosome 6 at p21.31 and consist of three different 
classes of genes, as shown in Figure 1.1(a). Class I and II genes are structurally and 
functionally related and play an essential role in allo-HCT. Class III genes are not directly  
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Figure 1.2 Illustration of the HLA gene nomenclature. 
involved in donor-recipient histocompatibility testing, however, they function through 
inflammatory reactions (Petersdorf et al. 2018). The HLA genes are further categorized 
into classical and nonclassical genes based on the gene polymorphism and the direct 
interactions with T cells. Classical class I genes include HLA-A, -B and -C. These genes 
have high polymorphisms in exons 2, 3 and 4 that define different alleles and encode an 
α1, an α2, and an α3 domain of the MHC molecules. As shown in Figure 1.1(b), the α1 
and the α2 domain form a peptide-binding groove which presents a peptide of 8 to 10 
amino acids in length to CD8+ T cells (Halenius, Gerke, and Hengel 2015). This region 
is called the antigen recognition domain (ARD). Similarly, HLA-DRB1 and -DQB1 
belongs to the classical class II genes, which encode MHC molecules that present 
peptides with more variable lengths, ranging from 10 to 20 amino acids to CD4+ T cells.  
 
Graft histocompatibility testing largely depends on the determination of the classical HLA 
gene allele types of graft stem cells and the patients, which is referred to as HLA typing. 
For effective communications across HLA typing laboratories, clinicians and 
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researchers, the Harmonization of Histocompatibility Typing Terms Working Group 
defined a consensual Histocompatibility Typing Terms (Nunes et al. 2011). The HLA 
typing results are reported based on the World Health Organization (WHO) HLA 
Nomenclature Report (Marsh and WHO Nomenclature Committee for Factors of the HLA 
System 2018) and the IMGT/HLA database (Robinson et al. 2015). Figure 1.2 shows an 
example of HLA allele in a four-field name. Low-resolution typing refers to the alleles 
with only one field (e.g., HLA-B*44:XX) which corresponds to a serologic equivalent 
(B44), and a high-resolution HLA typing usually includes alleles with two-field names 
(e.g., HLA-B*44:02), which indicates alleles that encode the same protein sequence on 
the ARD of the MHC molecule. When an allele cannot be determined at a high 
resolution, the allele is reported at between high- and low-resolution and is assigned the 
name mostly based on associated population and the common and well-documented 
alleles (Mack et al. 2013). 
 
In practice, the allele types at five classical HLA gene loci, i.e., HLA-A, -B, -C, -DRB1 
and -DQB1, are determined and matched for each DR pair. All five gene loci matched 
(10 of 10 allele-matched) allo-HCT cases have shown significantly improved survival 
rate and transplant outcomes (Fürst et al. 2013). However, approximately 40% of 
patients after 10/10 HLA-matched allo-HCT still suffer from relapse and non-relapse 
causes of death, such as GVHD (D’Souza and Zhu 2017). In allo-HCT, GVHD is the 
major cause of non-relapse morbidity and mortality, affecting up to 40~60% (M. Jagasia 
et al. 2012), accounting for 20% of deaths after allogeneic HSCT (Pasquini and Zhu 
2015). Maximizing the graft-versus-leukemia (GVL) effect and limiting GVHD has been 
the main research topic to improve the effectiveness of allo-HCT. Specifically, these 
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effects are caused by the polymorphic peptides presented on the surface of HLA Class 
I/II molecules, which activate the donor-derived cytotoxic T cells and subsequent 
immune responses. The influence of mismatches of classical HLA genes between donor 
and recipient on GVHD have mainly been investigated and well established at the ARD 
level (Fürst et al. 2013); however, there has not yet been an established study on the 
influence of mismatches of non-ARD exons and/or introns on the GVHD outcomes after 
allo-HCT.  
Pathogenesis of acute graft-versus-host disease  
GVHD is an immunologically mediated complex disease resulting from donor-derived T 
cell activation and attack on recipient normal cells due to the genetic disparities between 
donor and recipient. Clinically, GVHD has an acute form and a chronic form. Acute 
GVHD shows damaging symptoms on the skin, liver, and the gastrointestinal tract, while 
chronic GVHD has more diverse manifestations (for instance, nails, mouth, eyes) and 
sometimes resembles autoimmune syndromes. For epidemiological studies, these two 
forms were defined based on the symptoms that occur before or after Day 100 after 
transplantation. However, this definition does not correctly distinguish the two forms of 
GVHD, and hence a recent updated National Institutes of Health classification clarified 
the categorization and scoring form for acute and chronic GVHD by including late-onset 
acute GVHD (after Day 100) and the “common” features that indicate signs and 
symptoms found in both acute and chronic GVHD (M. H. Jagasia et al. 2015). Table 1.1 
and Table 1.2 show the severity of each organ in acute GVHD, and the overall clinical 
grading of acute GVHD adapted from 1994 Consensus Conference on acute GVHD 
grading (Przepiorka et al. 1995; Ball, Egeler, and EBMT Paediatric Working Party 2008). 
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The development of acute GVHD conceptually includes three main sequential phases 
(Ferrara et al. 2009), or more specifically five basic steps (Socié and Blazar 2009). The 
first phase includes the activation of antigen presenting cells (APCs) due to host tissue 
damage caused by the underlying disease or the allo-HCT conditioning regimen. The 
second phase is activation and expansion of donor-derived T cells in response to the 
host and graft APCs as well as inflammatory cytokines (Bader et al. 2004). The last 
phase is an effector phase with a complex cascade of both cellular mediators (cytotoxic 
T lymphocytes, NK cells) and inflammatory mediators (TNF-α, INF-γ, IL-1). The 
dysregulation of cytokines resulted from these mediators eventually leads to the clinical 
manifestations of acute GVHD (Antin and Ferrara 1992; Couriel et al. 2004; Zeiser et al. 
2004; Ball, Egeler, and EBMT Paediatric Working Party 2008). 
 
The genetic disparities between donor and patient lead to the immunogenic polymorphic 
peptides, or the minor histocompatibility antigens (MiHAs). To the best of our knowledge, 
a very limited number of HLA restricted MiHAs have been identified and characterized in 
the literature, and the global roles of these MiHAs on the development of acute GVHD 
remain to be understood. Griffioen et al. reviewed forty-eight HLA Class I-restricted and 
eight HLA Class II-restricted autosomal MiHA genes that have been discovered and 
characterized through in vivo immune responses (Griffioen, van Bergen, and Falkenburg 
2016). They were individually and specifically searched on candidate genes such as 
HLA-ligandomes, hematopoiesis-restricted genes and single nucleotide polymorphism 
(SNP) association with the clinical outcome after transplantation. However, the 
interactions among these SNPs is still unclear, as well as their collective influences on 
acute GVHD. 
 8 
To date, genome-wide association studies (GWAS) and candidate gene studies have 
identified SNPs associated with acute GVHD, including SNPs that cause the genetic 
disparities between the donor and the patient, i.e. MiHA SNPs (Griffioen, van Bergen, 
and Falkenburg 2016), and SNPs that modify gene functions (Petersdorf et al. 2015). 
However, the genetic risks for acute GVHD outcome have not been well defined yet 
(Hansen et al. 2010). Most such studies have focused on single locus variations 
individually and tested them for association with acute GVHD. Unlike the underlying 
assumptions of these studies, however, genes tend to work interactively within specific 
functional pathways, contributing to the disease phenotypes. 
 
It is reported that non-HLA genetic factors also play an essential role in HLA-identical 
allo-HCT (Yang and Sarwal 2017), including immune response and regulatory pathway 
gene polymorphisms (Lin et al. 2005b; Mullally and Ritz 2007), ki ller-cell 
immunoglobulin-like receptors (KIRs)(Littera et al. 2012), MHC Class I polypeptide-
related sequence A (MICA) (Park et al. 2016; Chojecki 2017; Fuerst et al. 2016), and 
minor histocompatibility antigens (MiHAs) (Griffioen, van Bergen, and Falkenburg 2016; 
Martin et al. 2017). These factors may trigger allo-immune responses in the recipient 
who has received HLA-identical stem cell transplant, either through incompatible 
receptor-ligand interactions or encoding non-self peptides that trigger the donor’s 
immune cells. Non-HLA gene studies are mainly targeted on the immune response 
related genes (candidate gene approach); however, the complex interactions among 
different genes in acute GVHD after HLA-identical allo-HCT remains to be understood. 
Gene-gene interaction, or epistasis, in the context of allogeneic transplantation, exhibits 
its unique features and challenges, compared to epistasis in traditional population 
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Table 1.1 Organ staging of acute GVHD, adapted from Przepiorka et al. (Przepiorka et al. 1995) 
Stage Skin Liver GI Tract 
0 No rash due to GVHD Bilirubin (< 2.0 mg/100 ml)  None (< 280 ml/m2) 
I Maculopapular rash 
<25% of body surface 
area without associated 
symptoms  
Bilirubin (2.0–3.0 mg/100 ml)  Diarrhea >500–1000 
ml/day (280–555 
ml/m2); nausea and 
emesis  
II Maculopapular rash or 
erythema with puritis or 
other associated 
symptoms ≥25% of 
body  
Bilirubin (3.0–5.9 mg/100 ml)  Diarrhea 1000–1500 
ml/day (556–833 
ml/m2); nausea and 
emesis  
III Generalized 
erythroderma; 
symptomatic macular, 
papular or vesicular 
eruption with bullous 
formation or 
desquamation covering 
≥50% of body surface 
area  
Bilirubin (6.0–14.9 mg/100 ml)  Diarrhea >1500 ml/day 
(>833 ml/m2); nausea 
and emesis  
IV Generalized exfoliative 
dermatitis or bullous 
eruption  
Bilirubin (>15 mg/100 ml)  Diarrhea >1500 ml/day 
(>833 ml/m2); nausea 
and emesis. Abdominal 
pain or ileus 
GI: Gastrointestinal tract 
Table 1.2 Clinical grading of the severity of acute GVHD,  
adapted from Przepiorka et al. (Przepiorka et al. 1995) 
Grade Skin Liver GI tract Functional impairment  
0 0 0 0 0 
I 1–2 0 0 0 
II 1–3 1 1 1 
III 2–3 2–3 2–3 2 
IV 2–4 2–4 2–4 2–4 
GI: Gastrointestinal tract 
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Figure 1.3 Genetic factors that influence the acute GVHD outcome in allo-HCT 
genetic models where the interactions are modeled under the assumptions of different 
inheritable genetic models (e.g., additive, dominant, recessive models). In the case of 
transplantation, it is likely that the synergistic interactions of several genes in a 
biochemical pathway from both the donor and the recipient play more critical roles in the 
development of acute GVHD. For example, the synergism between IL10 gene of the 
recipient and IL10 receptor 𝛽 gene of the donor in the IL10 metabolic pathway reportedly 
modulates the severity of acute GVHD (Lin et al. 2005a; Tseng et al. 2009). Figure 1.3 
shows the genetic factors that are involved in the development of acute GVHD.  
Main contributions of the dissertation 
Chapter 2 explores the HLA classical gene sequence diversity at scale and evaluates 
the mismatches outside the ARD region between ARD matched donor and recipient and 
their potential impact on the transplant outcomes. This research is the first systematic 
evaluation of the role of mismatches outside the ARD of the classical HLA genes on the 
allo-HCT outcomes. Additionally, the bioinformatics pipeline incorporates multiple 
sequence analysis with functional annotation for donor-recipient pairs. Note that the HLA 
Class II genes are highly prone to misalignment due to their extremely long and 
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polymorphic intron regions if aligned directly to the whole gene reference sequences. 
Targeted region alignment for Class II genes in the proposed pipeline significantly 
improves the alignment accuracy. All these features will benefit the HLA research 
community and provide new insights on HLA mismatch types in allo-HCT outcomes. 
This work has been presented in the 42nd and 44th ASHI annual symposiums, 
respectively (H. Huang et al. 2016, 2018). 
 
In Chapter 3, we expand our focus on the mismatches between donor and recipient to 
the whole genome level. We developed a bioinformatics analysis pipeline to compare 
the genomic sequences between donor and recipient, especially the non-synonymous 
mismatches restricted by HLA typing. We successfully identified Y-chromosome 
encoded minor histocompatibility antigens in sex-mismatched transplant cases that may 
be directly linked the acute GVHD symptoms. The bioinformatics tools provide a 
systematic analysis of whole genome sequences of the HLA-matched donor-recipient 
pairs and identify potential MiHAs efficiently in silico. This work has been published in 
Blood Advances (W. Wang et al. 2018).  
 
The complex transplant-related outcome goes beyond the genetic mismatches between 
donor and recipient. In Chapter 4, we therefore propose a data mining technique to 
investigate the complex genetic relationships among donor and recipient genomes and 
the transplant outcomes. Specifically, we develop a feature selection method, called 
iRBA-RF, to identify the most informative SNPs that are linked to the transplant outcome 
(e.g., acute GVHD) and provide possible biological functional explanations. The 
proposed model does not require prior biological knowledge, such as the functional 
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pathways and immunological signatures or any assumptions. The framework examines 
gene sets and their association with the transplant outcomes, as opposed to 
investigating individual genes associated with the outcomes, which is the current state in 
the literature. The proposed algorithm provides novel bioinformatics tools for transplant 
genomic studies where exploring the ultra-high dimensional genotype data is one of the 
biggest challenges. It will bring new insights into understanding genetic factors that drive 
GVHD/GVL effects after HLA-matched allogeneic HSCT. This work has been submitted 
to a peer-reviewed journal and undergoing the manuscript review process. 
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Chapter 2 HLA gene sequence diversity and the 
impact of sequence mismatches in allogeneic 
hematopoietic stem cell transplantation 
outcomes 
 
Abstract 
In allogeneic hematopoietic stem cell transplantation (allo-HCT), HLA allele matching 
between donor and recipient (DR) has traditionally focused on the polymorphic antigen 
recognition domain (ARD). While mismatching at the ARD is known to influence 
transplant outcomes, it is unclear about the role of the mismatches outside the ARD. An 
estimate of up to 70% of the allo-HCT recipients still develops post-transplant 
complications, such as acute graft-versus-host disease (GVHD), even after the use of 10 
out of 10 (HLA-A, -B, -C, DRB1, -DQB1) HLA allele-matched unrelated donors. In order 
to determine whether the sequence mismatches outside the ARD region are linked to 
the transplant-related complications, we assessed the genetic sequence variations of the 
classical HLA genes at a general population and characterized the frequency of 
mismatches in non-ARD regions when DR pairs are matched at the ARD level. The 
analysis of 15,865 healthy donors’ classical HLA gene sequences revealed that in 
addition to the expected high sequence variations in the ARD region, the noncoding 
regions (5’-, 3’- untranslated regions and introns) and non-ARD exons also exhibit high 
sequence diversities. Despite the high sequence variation across different regions, a 
 14 
subsequent analysis of 4,646 10/10 HLA matched DR pairs’ HLA gene sequences 
showed limited mismatches outside the ARD regions. For HLA Class I alleles, 95.19% of 
the ARD matched alleles have identical sequences across the whole gene region. 0.67% 
of the mismatches were synonymous variants from the ARD region, while 0.17% and 
0.10% of mismatches observed in the non-ARD exons were synonymous and 
nonsynonymous variants, respectively. The intronic variation accounted for 4.39% of the 
mismatches. Similarly, for HLA Class II alleles, 0.28% of mismatches were synonymous 
ARD variants, and the mismatches in the non-ARD exons were also very rare 
(synonymous: 0.28%; nonsynonymous: 0.16%). A high degree of variation was 
observed in the intronic regions of the HLA class II genes, with only 77.3% of the allele 
pairs shared having identical sequences. Overall, 0.22% and 4.56% of HLA class I and 
class II allele pairs, respectively, showed both exon and intron mismatches. In 
conclusion, due to the low frequency of amino acid mismatches in the non-ARD region 
and their reportedly weak allo-immune reactions, we suggest that the non-ARD 
sequence mismatches within 10/10 HLA ARD matched DR pairs have limited influence 
on the development of post-transplant complications, such as acute GVHD, and may not 
be a primary factor. 
 
Keywords: human leukocyte antigen (HLA), antigen recognition domain, allogeneic 
hematopoietic stem cell transplantation (allo-HCT), graft-versus-host disease (GVHD) 
Introduction 
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the main curative 
treatment option for a series of blood and bone marrow related disorders, including 
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leukemia and lymphoma. One of the most crucial criteria in allo-HCT is to identify the 
histocompatibility (tissue compatibility) between the potential donor and the patient. The 
human leukocyte antigen (HLA) complex genes, also known as the major 
histocompatibility complex (MHC) genes, play a critical role in determining the 
histocompatibility of a potential donor with a recipient in a stem cell transplant. HLA 
complexes recognize and bind to antigens produced from non-self proteins and initiate 
corresponding immune responses, causing graft rejection, graft-versus-host disease 
(GVHD), and other post-transplant disorders.  
 
For allo-HCT purposes, the ideal donors are HLA genotypically identical siblings of the 
patients. In theory, the likelihood of having such a donor for a patient depends on the 
number of siblings, for instance, 25% for those with one sibling, 44% for those with two 
siblings, and 58% for those with three. Besse et al. showed that the actual probability of 
having an HLA-identical sibling depends on the patient’s age and their ancestry 
information and that in the U.S., only 13% to 51% of patients can find such a sibling 
donor (Besse et al. 2016). In other words, 49% to 87% of allo-HCT patients are expected 
to rely on an unrelated donor source. The current gold standard for donor selection is to 
test the HLA compatibility of 10 alleles at five classical HLA loci, i.e., HLA-A, -B, -C, -
DRB1, and -DQB1, as mismatches at either of these locus are significantly associated 
with deteriorated survival rates and post-transplant complications (S. J. Lee et al. 2007; 
Fürst et al. 2013; Petersdorf 2015; Morishima et al. 2015; Kekre et al. 2016; Petersdorf 
2017). Specifically, several multicenter retrospective allo-HCT outcome studies have 
shown that single-allele mismatched transplant cases have an estimated risk of acute 
GVHD ranges from 13% to 69% (Ciurea et al. 2011; Nakamae et al. 2010; Mehta et al.  
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Figure 2.1 The dramatic growth of curated HLA classical gene alleles since 1998 (v1.0) from 964 
alleles to 16,040 alleles (v3.31.0). 
2004; Kekre et al. 2016). Thus, HLA-A, -B, -C, -DRB1, -DQB1 (10/10) allele-matched 
unrelated donors are considered as the optimal alternatives when HLA identical siblings 
are not available. 
 
In practice, only the genetic regions in HLA genes that encode the antigen binding 
groove are characterized and compared between the potential donor and the recipient. 
The influence of genetic mismatches within the antigen-recognition domain (ARD) on the 
transplant outcome has been primarily investigated and well characterized based on the 
assumption that the ARD mismatches are the major player in the post-transplant 
complications. However, little is known about the functional implication of mismatches 
outside the ARD on allo-HCT outcomes.  
 
The high-throughput next-generation sequencing (NGS) platform has enabled the 
accurate and high-resolution typing of HLA genes. As a result, novel alleles have been  
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Table 2.1 Summary of curated HLA classical gene alleles 
in IMGT/HLA database (v3.31.0) (January 2018) 
HLA Gene Class Locus #Alleles #Full-length alleles %Full-length alleles 
Class I HLA-A 4,080 849 20.8 % 
HLA-B 4,948 969 19.6 % 
HLA-C 3,684 873 23.7 % 
*Class II HLA-DRB1 2,146 87 4.1 % 
HLA-DQB1 1,176 173 14.7 % 
Total 16,034 2,951 18.4 % 
* HLA Class II genes have extremely long intronic sequence (over 2000 bp). It is difficult 
accurately sequence the full gene region. For HLA class II genes, the sequences that cover from 
intron 1 through intron 3 are counted towards the “full-length alleles” in this summary.  
 
discovered at a tremendous rate in recent years, as shown in Figure 2.1. However, due 
to the particular interest on the ARD regions as well as challenges in characterizing full 
gene region sequences, as of January 2018, only less than 19% of the recognized 
classical five loci HLA alleles (HLA-A, -B, -C, -DRB1, -DQB1) have characterized full-
length gene sequences or sequences outside the ARD region in the IMGT/HLA 
database Release 3.31.0, as shown in Table 2.1 (Robinson et al. 2015; Marsh and WHO 
Nomenclature Committee for Factors of the HLA System 2018; European Bioinformatics 
Institute 2018). For HLA Class II alleles (HLA-DRB1 and -DQB1), the extremely long and 
repetitive intron regions (over 2000 bp) pose challenges on sequence alignment, 
assembly, and haplotype assignment, so that less than 8% of recognized Class II genes 
have characterized sequences outside ARD. Sequence variations outside the ARD 
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region are not well characterized, and the impact of donor-recipient (DR) pair HLA 
mismatches in non-ARD regions are poorly understood.  
 
Based on the HLA nomenclature system, alleles that share the same nucleotide 
sequence in the ARD regions are designated as the G allele groups, while alleles that 
encode the same polypeptide sequences in this region are designated as the P allele 
groups(Marsh and WHO Nomenclature Committee for Factors of the HLA System 2018). 
For instance, HLA-A*01:01:01G includes 72 alleles that have the same ARD exon 
sequences but different sequences in non-ARD exons and non-coding regions [5’-, 3’-
untranslated region (UTR) and introns]. Similarly, HLA-A*01:01P includes 157 alleles 
that encode the same polypeptides in ARD region but different amino acid sequences in 
the rest of the HLA molecule. The impact of amino acid substitutes outside the ARD 
region in the G group alleles on T cell recognition has not been well characterized, 
except the case where it results in the loss of HLA expression that affects the 
allorecognition process. 
 
Studies have shown that up to 70% of the patients who undergo 10/10 HLA matched 
unrelated allo-HCT still suffer from post-transplant complications, such as acute GVHD 
(Shaw et al. 2017; D’Souza and Zhu 2017). The purpose of this study is to determine 
whether the sequence mismatches outside the ARD region are linked to these 
transplant-related diseases after 10/10 HLA matched allo-HCT. We first assess the 
genetic sequence variations of the classical HLA genes at a general population, 
especially the non-ARD exons and non-coding regions, and then characterize the 
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frequency of mismatches in non-ARD regions when DR pairs are fully matched at the 
ARD level.  
Materials and methods 
Healthy donors’ HLA gene sequences for gene sequence diversity 
analysis 
15,865 healthy donors including four broad races (African American: 15.4%; Asian and 
Pacific Islander: 11.6%; Caucasian: 22.0%; Hispanic Origin: 28.9%; Native American: 
22.1%) were selected from the Be The Match Registry® operated by the National 
Marrow Donor Program. The HLA Class I (HLA-A, -B, -C) alleles were sequenced 
through the Illumina MiSeq platform (Illumina, San Diego, CA). Several thousand pair-
ended short reads (150 bp) were then assembled into consensus sequences that 
include from 5’-untranslated region (UTR) to 3’-UTR. HLA Class II (HLA-DRB1, -DQB1) 
alleles have extremely long intronic regions with repetitive nucleotide sequence blocks. 
For instance, introns 2 and 3 of the HLA-DRB1 gene are 2,229 bp and 701 bp long, 
respectively, whereas exons 2 and 3 are only 270 bp and 282 bp long, respectively. 
These intron regions lead to a challenge in characterizing the full-length allele 
sequences. Typically, a targeted sequencing scheme is employed to extract the 
sequences of exons 2 and 3 for HLA Class II alleles. Here we employed the Pacific 
Biosciences RS-II platform to obtain high-quality elongated sequences with partial 
intronic regions. 
 
Multiple sequence alignment was performed on the five loci allele sequences using  
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Clustal Omega (Sievers et al. 2011), and low-quality sequences were removed from the 
downstream analysis. This was followed by a gene annotation pipeline to annotate exon 
and intron regions. We employed the Shannon entropy of each aligned nucleotide site at 
each of the five loci to characterize the allele diversity. The Shannon entropy is defined 
as  
 
where  is the frequency of each nucleotide type in the cohort. If all four types of 
nucleotides (A, T, C, and G) have an equal frequency (25%) at a position, then this 
position has the maximum entropy of 2 (or 2.32 in the case of considering alignment 
gaps as there are five possible values at each position, i.e., A, T, C, G and a gap), and 
hence it is considered the most variable position. At a most conserved position, there is 
only one type of nucleotides, and the entropy has the minimum value of 0.   
Donor-recipient pair HLA gene sequences comparison 
A cohort of 10/10 (HLA-A, -B, -C, -DRB1, -DQB1) high-resolution matched retrospective 
transplant cases (n=4,646) performed between 2000 and 2017 was selected from the 
Center for International Blood and Marrow Transplant Research (CIBMTR) Repository, 
and the donor-recipient pairs’ HLA gene alleles were sequenced. HLA Class I alleles 
were sequenced through the Pacific Biosciences RS-II platform to characterize the full 
gene regions, whereas HLA Class II alleles were sequenced through the Illumina MiSeq 
platform for targeted exon regions. Figure 2.2 shows the developed comprehensive HLA 
allele sequence comparison pipeline that identifies and annotates the mismatched 
positions between two alleles by their functional regions and their protein sequence  
 21 
 
Figure 2.2 Diagram of the donor-recipient pair HLA gene sequence comparison pipeline 
 
 
(a) 
 
(b) 
Figure 2.3 Targeted alignment for HLA class II gene sequences 
differences using IMGT/HLA Database (v3.31.0). The sequence alignment for 
comparison was performed through the MUSCLE algorithm (Edgar 2004). 
 
The HLA Class II gene sequences often reported with partial intronic regions, as shown 
in Figure 2.3(a), which can cause misalignment when the query sequences are aligned 
against the full-length reference sequence. For instance, the exon region of the query 
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sequence may be stretched to the intron region after alignment with gaps in between. In 
order to avoid this issue, we adopted a target region alignment, i.e., instead of aligning 
against the full-length reference sequence, the query sequences were aligned against 
only exons 2 and 3 from the reference, respectively, as shown in Figure 2.3(b). This 
strategy significantly improved the alignment accuracy and efficiency for HLA Class II 
genes.   
Results 
Information theory-based measurement shows the genetic sequence 
variations in non-ARD exons and non-coding regions are as diverse 
as in the ARD regions. 
Figure 2.4 shows the nucleotide variation across the alignment positions. After 
alignment, the untranslated regions (URTs) generally show a high sequence variation for 
HLA Class I alleles. This may be due to the high polymorphism in the UTR regions; on 
the other hand, it also may be caused by the varying lengths of UTR regions for different 
alleles which introduced gaps in the alignment. In order to investigate the genetic 
variation without the alignment gaps, the positions with at least one gap were artificially 
given the value of -0.5 to filter out from the scatter plot, as shown in the right column of 
Figure 2.4.  
 
Figure 2.5 illustrates the entropy distribution in each functional region. As expected, the 
ARD regions show high sequence variation in general (entropy values between 0.01 and 
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Figure 2.4 HLA class I gene alignment and their sequence diversity. Left column shows the 
entropy changes on the original alignment, and the right column shows the entropy after 
removing gaps from alignment. The positions which have at least one gap is given the value of  
-0.5. The shaded areas indicate exon regions. 
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Figure 2.5 HLA class I gene sequence variable sites by functional regions after sequence 
alignment. Left column: distribution of entropy values in each region; Right column: the proportion 
of diverse position within each region above different entropy thresholds. 
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Figure 2.6 HLA class II gene alignment and their sequence. 
 Left column: shaded area shows exon 2 while the rest shows exon 3. 
 Right column: proportion (%) of variation sites within exons 2 and 3.  
0.5). Highly variable sites (entropy>0.01) appear mostly in the noncoding regions (intron 
3 in HLA-A; introns 3 and 4 in HLA-B; introns 2, 3 and 5 in HLA-C). Among non-ARD 
exon regions, exons 5 and 6 show high variation. For HLA Class II alleles, due to the 
incomplete intron sequences and alignment challenges, we only assessed the exons 2 
and 3. Figure 2.6 shows similar results as HLA Class I genes, where non-ARD exon 
(exon 3) also shows a high variation.  
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10/10 high-resolution ARD-matched donor-recipient pairs have 
limited mismatches outside the ARD region 
When a donor-recipient pair is matched at ARD regions, we observed very limited 
mismatches outside the ARD region. For HLA Class I alleles, 95.19% of the ARD 
matched alleles have identical nucleotide sequences between donor and recipient pairs. 
There are 0.3% of nucleotide sequence mismatches within the ARD region; however, all 
of them are synonymous variants, which are translated into the same protein sequences. 
In the non-ARD exon region, we observed 0.3% and 0.13% of synonymous and 
nonsynonymous nucleotide mismatches, respectively. The intronic variation accounted 
for 4.17% of the mismatches.  
 
Similarly, for HLA Class II alleles, 0.28% of mismatches were synonymous ARD variants, 
and the mismatches in the non-ARD exons were also very rare, including 0.28% 
synonymous and 0.16% nonsynonymous variants. However, due to the high 
polymorphism in the intronic regions of the Class II genes, 26.48% of mismatches were 
intronic, and only 77.3% of allele pairs shared identical nucleotide sequences. For some 
allele pairs, nucleotide mismatches were observed in more than one region 
simultaneously. Specifically, 0.22 % and 4.56% of Class I and Class II allele pairs, 
respectively, showed mismatches in more than one functional region (exon and intron). 
Table 2.2 shows the detailed breakdown of mismatched allele pairs by HLA gene locus. 
A total of 25 different allele pairs showed nonsynonymous variants in non-ARD exons 
leading to different amino acid sequences of the MHC molecules, as shown in Table 2.3. 
Seven of these allele pairs showed different protein structures in the transmembrane 
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Table 2.2 Percentage (%) of mismatches between alleles from 10/10 ARD matched donor-
recipient pairs HLA full gene sequences by locus. 
Syn: synonymous; non-syn: nonsynonymous; 
non-coding: intron and/or the untranslated regions (UTRs). 
Locus Identical 
(%) 
Syn ARD 
(%) 
Non-syn 
ARD (%) 
Syn 
non-ARD 
exon (%) 
Non-syn 
non-ARD 
exon (%) 
Non-
coding  
(%) 
Total # 
allele 
pairs 
A 95.19 0.67 0 0.17 0.10 4.39 9286 
B 96.64 0.17 0 0.17 0.13 2.96 9290 
C 94.50 0.05 0 0.18 0.16 5.17 9266 
DRB1* 77.58 0.03 0 0.17 0.23 22.20 9090 
DQB1* 77.08 0.53 0 0.45 0.10 30.67 9292 
Class I 95.44 0.30 0 0.30 0.13 4.17 27842 
Class II* 77.33 0.28 0 0.28 0.16 26.48 18382 
* Class II genes were sequenced at the following targeted regions: full-length exon 2 (270 bp) 
with partial intron 1 and partial intron 2, full-length exon 3 (282 bp) with partial intron 2 and partial 
intron 3.  
 
Table 2.3 Observed non-ARD nonsynonymous mismatched alleles between donor and recipient 
Allele 1 Allele 2 Exon/Intron location;  
amino acid change from 
Allele 1 to Allele 2;  
protein location 
Count of 
observed 
DR pairs 
Allele 2: 
Common 
and well 
docume
nted 
HLA-A*23:01:01  HLA-A*23:17 Exon 5; His283Pro; TM 3 WD 
HLA-A*02:01:01:01/02L HLA-A*02:66 Exon 4; Thr225Ile; α3 1 Not CWD 
HLA-A*02:01:01:01/02L HLA-A*02:559 Exon 4; His188Arg; α3 1 Not CWD 
HLA-A*02:01:01:01/02L HLA-A*02:09 Exon 4; Ala236Glu; α3 1 Common 
HLA-A*11:01:01:01 HLA-A*11:86 Exon 4; Gly221Arg; α3 1 Not CWD 
HLA-A*24:02:01:06 HLA-A*24:79 Exon 4; Gly265Asp; α3 1 Not CWD 
HLA-A*01:01:01 HLA-A*01:37 Exon 4; Thr228Met ; α3 1 Not CWD 
HLA-B*44:02:01:03 HLA-
B*44:27:01 
Exons 4, 5, 7; Val199Ala, 
Val282Ile, A305T, 
6 Common 
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Cys325Ser; α3, TM, Cyt  
HLA-B*35:01:01:01 HLA-B*35:57 Exon 4; Val194Ile; α3 3 Not CWD 
HLA-B*51:01:01:01 HLA-B*51:193 Exon 5; Ile282Val; TM 2 Not CWD 
HLA-B*07:05:01 HLA-B*07:06 Exon 5; Ile282Val; TM 1 Common 
HLA-C*07:01:01:01 HLA-C*07:18 Exon 6, Intron 4; 
Ala324Val; Cyt 
5 Common 
HLA-C*04:01:01:01 HLA-C*04:82 Exon 5; 
Leu300_Gly301insAVL; 
TM  
1 WD 
HLA-C*12:03:01:01 HLA-C*12:143 Exon 6; Ala325Val; Cyt 1 Not CWD 
HLA-C*05:01:01:02 HLA-C*05:03 Exon 4; Glu183Asp, 
His184Pro, Val194Ile, 
Ala199Val; α3 
1 Not CWD 
HLA-C*15:02:01:01 HLA-C*15:13 Exon 4; Glu229Gln; α3 1 WD 
HLA-DRB1*14:01:01 HLA-
DRB1*14:54:0
1 
Exon 3; Tyr112His; β2 20 Common 
HLA-DRB1*13:01:01 HLA-
DRB1*13:117 
Exon 3; Arg133Trp; β2 1 Not CWD 
HLA-DQB1*03:01:01/04 HLA-
DQB1*03:19:0
1 
Exon 3; Thr185Ile; β2 2 Common 
HLA-DQB1*06:02:01 HLA-
DQB1*06:111 
Exon 3; Gly141Ser; β2 2 Not CWD 
HLA-
DQB1*03:01:01:02/03 
HLA-
DQB1*03:19 
Exon 3; Thr185Ile; β2 1 Common 
HLA-
DQB1*03:01:01:01/02/03 
HLA-
DQB1*03:09 
Exon 3; Gly168Ala, 
Asp169del; β2 
1 Common 
HLA-DQB1*03:03:02:01 HLA-
DQB1*03:31 
Exon 3; Val116Ile; β2 1 Not CWD 
HLA-DQB1*02:01:01 HLA-
DQB1*02:02:0
1 
Exon 3; Asp135Gly; β2 1 Common 
HLA-DQB1*02:02:01 HLA-
DQB1*02:10 
Exon 3; Val142Ile; β2 1 Not CWD 
CWD: common and well-documented allele; WD: well-documented allele; TM: transmembrane; 
Cyt: cytoplasmic tail; CWD alleles are based on CWD release 2.0. 
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segment or the cytoplasmic tail, while the rest differed in α3 (Class I) or β2 (Class II) 
chain below the antigen binding cleft. Especially, HLA-B*44:02:01:03 and HLA-
B*44:27:01 differ in all three regions outside the ARD, i.e., α3-chain, the transmembrane 
segment, and the cytoplasmic tail. Twelve of the alternative alleles (shown as Allele 2 in 
Table 2.3) were categorized as common or well-documented alleles according to the 
CWD catalogue 2.0.0 (Mack et al. 2013).  
 
Discussion and conclusion 
MHC genes are the most polymorphic gene regions among known the human gene 
system (Janeway et al. 2001). In this study, we showed the sequence diversity of the 
classical HLA genes in a general population, especially the high sequence variations in 
the non-ARD exons as well as the noncoding regions (5’-, 3’-UTR, or introns). Although 
the ARD region has been the focus in the practice of HLA matching, the high sequence 
variation outside the ARD region may also exert influence on the transplant outcomes.  
 
The investigation of the 10/10 HLA matched transplant cases showed that the ARD-
matched DR pairs have limited mismatches in the non-ARD exons (0.43%) and we 
observed the nonsynonymous mismatches at an even lower rate (0.13%). Alleles that 
share the same ARD sequences likely have the same non-ARD exon sequences. The 
low mismatch rate in non-ARD exons may be due to the high degree of linkage 
disequilibrium between the exons of the HLA alleles (Smith et al. 2005). The intron 
sequence mismatches were observed at a higher rate (4.17% for Class I and 26.48% for 
Class II), which may be explained by the different evolutionary forces in coding and non-
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coding regions of HLA alleles (Cereb, Hughes, and Yang 1997; Meyer and Blasczyk 
2000; Bergström et al. 2000). Intron variation is caused by the combined effects of 
mutation, recombination, and selection and it is reported that the recombination events 
concentrated in the introns near ARD exons (Cereb, Hughes, and Yang 1997; Kotsch 
and Blasczyk 2000; Meyer and Blasczyk 2000). Our observation of high intronic 
sequence variations is consistent with these reports. For HLA Class II alleles, we 
observed a much higher rate (26.48%) of intronic mismatches than a prior report with a 
smaller sample size (less than 2% of intronic mismatches, n=360) (Hou et al. 2017). This 
discrepancy may be due to the differences in typing methodologies and sequencing of 
highly repetitive intronic regions. As noted by Hou et al., in order to assess the impact of 
non-ARD mismatches on clinical outcomes of allo-HCT, an outcome association study 
may need at least 5,916 transplant pairs according to a log-rank test for 80% power at a 
significant level of  (Hou et al. 2017).  
 
However, the analysis of 4,646 transplant cases in this study suggests that sequence 
mismatching rate outside the ARD region between ARD-matched donor and recipient is 
relatively low and the mismatches of the corresponding amino acid sequences may be 
uncommon. Moreover, a recent study based on in vitro T cell assays by Roelen et al. 
suggested that non-ARD polypeptide mismatches may result in weak immunogenicity as 
they observed minimal T cell reactivity (Roelen et al. 2018). Even when there are amino 
acid mismatches outside the ARD region, they are unlikely the leading player to trigger 
the allo-immune reaction. Thus, we suggest that the non-ARD sequence mismatches 
between donor and recipient have limited influence on the development of post-
transplant complications, such as acute GVHD, and may not be a primary factor.  
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Several retrospective analysis of allo-HCT cases confirmed that donor-recipient HLA 
matching at the ARD level is the most critical factor that influences overall survival and 
the development of acute GVHD (S. J. Lee et al. 2007; Fürst et al. 2013; Kollman et al. 
2016). Furthermore, when more than one HLA matching donor is available, non-HLA 
characteristics, such as donor age and sex, have shown to be linked to the post-
transplant complications (Kollman et al. 2016; Petersdorf 2017). In order to uncover the 
genetic mechanisms of the development of acute GVHD and facilitate donor selection 
for allo-HCT with better transplant outcomes, it will be beneficial for future research to 
investigate the non-MHC genes, genetic and immunologic regulatory pathways and 
donor-recipient synergistic interactions. In the next two chapters, we discuss the non-
MHC gene factors and a method to detect potential genetic interactions from the DR pair 
whole genome sequences.  
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Chapter 3 Chromosome Y-encoded antigens 
associate with acute graft-versus-host disease in 
sex-mismatched stem cell transplant 1 
Abstract 
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a curative option for 
blood cancers, but the coupled effects of graft-versus-tumor and graft-versus-host 
disease (GVHD) limit its broader application. Outcomes improve with matching at HLAs, 
but other factors are required to explain residual risk of GVHD. In an effort to identify 
genetic associations outside the major histocompatibility complex, we conducted a 
genome-wide clinical outcomes study on 205 acute myeloid leukemia patients and their 
fully HLA-A, -B, -C, -DRB1, and -DQB1–matched (10/10) unrelated donors. HLA-DPB1 
T-cell epitope permissibility mismatches were observed in less than half (45%) of acute 
GVHD cases, motivating a broader search for genetic factors affecting clinical outcomes. 
A novel bioinformatics workflow adapted from neoantigen discovery found no 
                                               
1 This research was originally published in Blood Advances. “Wei Wang*, Hu Huang*, Michael 
Halagan, Cynthia Vierra-Green, Michael Heuer, Jason E. Brelsford, Michael Haagenson, Richard 
H. Scheuermann, Amalio Telenti, William Biggs, Nathaniel M. Pearson, Julia Udell, Stephen 
Spellman, Martin Maiers, and Caleb Kennedy. Chromosome Y–encoded antigens associate 
with acute graft-versus-host disease in sex-mismatched stem cell transplant. Blood 
Advances 2, no. 19 (2018): 2419-2429.” © the American Society of Hematology.  
W.W. and H.H. made equally substantial contributions to this research. The main contributions of 
H.H. include the development of bioinformatics workflows to analyze the whole-genome 
sequence data, identity-by-descent (IBD) calculation, result visualization and interpretation, and 
manuscript review.   
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associations between acute GVHD and known, HLA-restricted minor histocompatibility 
antigens (MiHAs). These results were confirmed with microarray data from an additional 
988 samples. On the other hand, Y-chromosome–encoded single-nucleotide 
polymorphisms in 4 genes (PCDH11Y, USP9Y, UTY, and NLGN4Y) did associate with 
acute GVHD in male patients with female donors. Males in this category with acute 
GVHD had more Y-encoded variant peptides per patient with higher predicted HLA-
binding affinity than males without GVHD who matched X-paralogous alleles in their 
female donors. Methods and results described here have an immediate impact for allo-
HCT, warranting further development and larger genomic studies where MiHAs are 
clinically relevant, including cancer immunotherapy, solid organ transplant, and 
pregnancy. 
Introduction 
Allogeneic hematopoietic cell transplantation (allo-HCT) can cure certain inherited 
diseases and acquired malignancies of the blood, yet biological mechanisms that 
provide beneficial effects, such as graft-versus-tumor (GVT),(Copelan 2006; Horowitz et 
al. 1990; Miller et al. 2010) also contribute to life-threatening graft-versus-host disease 
(GVHD)(Ferrara et al. 2009). Outcomes improve dramatically with donor-recipient 
matching of HLAs, but GVHD still occurs at frequencies of up to 70% in fully matched 
unrelated pairs, and to a lesser degree in related, HLA-identical transplant recipients 
(Gooley et al. 2010), suggesting unaccounted-for genetic factors impact clinical 
responses. 
 
Minor histocompatibility antigens (MiHAs) are germline-encoded immunogenic peptides 
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presented by specific HLA molecules on the surface of cancer cells or normal tissues. 
Although donor and recipient mismatching at the major histocompatibility complex 
(MHC) confers the highest proportional risk of GVHD, many clinically relevant MiHAs 
with defined HLA restriction have been identified (Oostvogels, Lokhorst, and Mutis 
2016), including Y-chromosome–encoded antigens that affect outcomes in sex-
mismatched HCT (Popli et al. 2014). In other nonmalignant conditions, such as solid 
organ transplant or pregnancy, MiHAs carry risk of rejection (Kim and Gill 2009; Wagner 
2012; Pfeffer and Thorsby, n.d.) or miscarriage (Christiansen, Steffensen, and Nielsen 
2011; H. S. Nielsen et al. 2010), respectively. 
 
In leukemia, there is evidence for tumor-specific antigenicity by exogenous activation of 
gene expression (J. Molldrem et al. 1996; J. J. Molldrem et al. 1999; Gao et al. 2000), 
gene fusion (Cai et al. 2012), and alternative splicing (Pont et al. 2016). In all cancers, 
driver and passenger mutations mark tumor progression (Lindsley et al. 2017; Lazarian, 
Guièze, and Wu 2017; Alexandrov et al. 2013), which may guide biomarker discovery 
(Falchook et al. 2016; A. C. Huang et al. 2017) and individualized treatment (Budczies et 
al. 2017; Strønen et al. 2016; Rajasagi et al. 2014). A subset of cancer variants give rise 
to immunoreactive neoantigens encoded by somatic changes in tumor DNA, and these 
changes are presented exclusively by tumors and targeted by patients’ normal immune 
systems (Tran et al. 2015). In a clinical setting, this effect may theoretically be exploited 
for GVT in allo-HCT (Burkhardt and Wu 2013) or precision medicine approaches to 
cancer immunotherapy. 
 
Despite the physiological connection between MiHAs and neo-antigens, there are 
important differences that should guide genomic analysis. Neoantigen discovery from 
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DNA or RNA sequences requires high sensitivity to detect rare or private variants from 
heterogenous tumor tissue (Y.-C. Lu and Robbins 2016), which is often chemically 
preserved (Srinivasan, Sedmak, and Jewell 2002). Sequencing patient and adjacent 
normal samples adds cost but also reduces false positives (Jones et al. 2015; Garofalo 
et al. 2016). MiHAs, on the other hand, arise from heritable germline polymorphisms that 
may be common in populations and accessible with less expensive microarrays or 
lower-coverage sequencing panels (Sampson et al. 2014). In both cases, antigens are 
only immunoreactive if they are displayed by patient HLA in affected tissues. Therefore, 
it is important to annotate variants with predicted MHC restriction, binding affinity, and 
tissue-specific expression. 
 
We sought a controlled, clinical-outcomes–based study in HLA-matched donor–recipient 
pairs to discover genetic variation outside the MHC that may contribute to the risk of 
acute GVHD following allo-HCT. 
Methods 
Study design 
The study population consisted of high-resolution HLA-A–, HLA-B–, HLA-C–, HLA-
DRB1–, and HLA-DQB1–matched (10/10) unrelated donor and recipient allo-HCT pairs. 
Patients were selected to obtain equal numbers with and without clinical evidence of 
grade II-IV acute GVHD, which was assessed as described based on severity or degree 
of organ involvement before day 100 after transplant (Deeg and Antin 2006). All patients 
received myeloablative conditioning for acute myeloid leukemia (AML) or other blood 
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cancers in complete remission (CR1 or CR2). After quality control and other filtering (see 
Methods), acute GVHD positive and negative cohorts were balanced for age, disease 
status, self-reported race or ethnicity, GVHD prophylaxis, and other factors (Table 3.1). 
Clinical data collection 
Clinical data were collected by the Center for International Blood and Bone Marrow 
Transplant Research (CIBMTR), a collaboration between the National Marrow Donor 
Program and the Medical College of Wisconsin representing a worldwide network of 
transplant centers that contribute detailed data on HCT. The CIBMTR conducts research 
in compliance with all applicable federal regulations pertaining to the protection of 
human research participants. All participants provided informed consent for participation 
in the CIBMTR research program, including submission of biological samples to the 
Research Repository, and this study was approved by the National Marrow Donor 
Program Institutional Review Board. 
HLA typing and histocompatibility matching 
HLA matching was determined at high resolution for HLA-A, HLA-B, HLA-C, HLA-DRB1, 
and HLA-DQB1 through retrospective typing of stored pre-transplant samples and/or 
reported by the transplant center and match assessment performed per CIBMTR criteria 
as previously described (Spellman et al. 2008). 5-locus haplotype matching was 
performed with the HapLogic algorithm (Dehn et al. 2016). 
Whole-genome sequencing 
250 donor and 250 HCT recipient samples (500 samples total) were sequenced at  
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Human Longevity, Inc. (San Diego, CA) to a mean coverage depth of 303 with 2 3 150 
bp paired reads using Illumina HiSeq X instruments. 125 pairs came from transplants 
with clinical evidence of acute GVHD; 125 pairs came from transplants without evidence 
of GVHD. Ten recipient samples did not produce adequate sequencing data. A further 2 
recipient samples and 1 donor sample failed the heterozygosity test that was applied to 
remove contaminated samples. An additional 32 samples were missing data for their 
paired donor or recipient and were removed from analysis. The final set included 205 
pairs of donor-recipient samples (102 acute GVHD and 103 non-GVHD). Secondary 
analysis with Isaac alignment and variant calling pipeline (Raczy et al. 2013) resulted in 
1 binary alignment map (Li et al. 2009) and 1 variant call format (Danecek et al. 2011) 
file per sample using the human genome reference assembly hg38. Variants with below 
average read depth (30X) were excluded from analysis. 
Microarray data and analysis 
The microarray data and primary analysis for Supplementary Table 3.1 have been 
described previously (Madbouly et al. 2017). 
Bioinformatics 
Genomic similarity was measured using identity-by-descent (IBD) sequencing with 
default parameters (Browning and Browning 2013). This technique determines phase for 
donor and patient genotypes to form haplotype segments of varying lengths, which 
indicate common ancestry. Normalizing the lengths of these segments to those of 
specific genomic features (including the whole genome itself) gives a relative measure of 
genetic similarity for each feature (Figure 3.1). For comparison, the null distribution of  
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Table 3.1 Counts of patients and donors in the acute graft-versus-host (GVHD) and non-GVHD 
groups. P-values were calculated using the Pearson chi-square test for comparing discrete 
variables or the Kruskal-Wallis test for comparing continuous variables. Abbreviations: CR – 
complete remission, PBSC – peripheral blood stem-cells, TCE – T cell epitope, CMV – 
cytomegalovirus. 
  AGVHD No AGVHD   
Variable N (%) N (%) p-value 
Number of Recipients 102 103   
Number of centers 47 50   
Patient-related       
Recipient age at transplant     0.09 
   0-9 years 3 (3) 1 (1)   
   10-19 years 10 (10) 6 (6)   
   20-29 years 16 (16) 17 (17)   
   30-39 years 21 (21) 15 (15)   
   40-49 years 23 (23) 42 (41)   
   50-59 years 29 (28) 22 (21)   
   Median (Range) 41 (1-66) 44 (9-66) 0.58 
Recipient race/ethnicity     0.79 
   Caucasian, non-Hispanic 87 (92) 94 (92)   
   African-American, non-Hispanic 1 (1) 2 (2)   
   Asian, non-Hispanic 2 (2) 3 (3)   
   Hispanic, Caucasian 5 (5) 3 (3)   
   Unknown 7 (N/A) 1 (N/A)   
Recipient sex     0.009 
   Male 64 (63) 46 (45)   
   Female 38 (37) 57 (55)   
Karnofsky score     0.47 
   10-80 24 (24) 32 (31)   
   90-100 72 (71) 66 (64)   
   Missing 6 (6) 5 (5)   
Disease-related       
Disease status at transplant     0.61 
   Early (CR1) 71 (70) 75 (73)   
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   Intermediate (CR2+) 31 (30) 28 (27)   
Transplant-related       
Stem cell source     0.24 
   Marrow 27 (26) 35 (34)   
   PBSC 75 (74) 68 (66)   
TCE nonpermissiveness     0.22 
   Ambiguous DPB1 allele 0 1 (1)   
   Permissive DPB1 54 (54) 62 (63)   
   Non-permissive DPB1 46 (46) 35 (36)   
   Data Missing 2 (N/A) 5 (N/A)   
GVHD Prophylaxis     0.80 
   Tacrolimus + MMF +- others 22 (22) 20 (19)   
   Tacrolimus + MTX +- others (except MMF) 56 (55) 57 (55)   
   Tacrolimus + others (except MTX, MMF) 5 (5) 2 (2)   
   Tacrolimus alone 3 (3) 1 (1)   
   CSA + MMF +- others (except Tacrolimus) 2 (2) 3 (3)   
   CSA + MTX +- others (except Tacrolimus, 
MMF) 
12 (12) 18 (17)   
   CSA + others (except Tacrolimus, MTX, MMF) 1 (1) 1 (1)   
   CSA alone 1 (1) 1 (1)   
Donor/Recipient sex matching     0.007 
   Male/Male 44 (42) 40 (39)   
   Male/Female 24 (25) 38 (37)   
   Female/Male 21 (21) 6 (6)   
   Female/Female 13 (13) 19 (18)   
Donor/Recipient CMV serostatus     0.68 
   Negative/Negative 33 (32) 29 (28)   
   Negative/Positive 37 (36) 36 (35)   
   Positive/Negative 10 (10) 14 (14)   
   Positive/Positive 19 (19) 23 (22)   
   Unknown 3 (3) 1 (1)   
Donor age at donation     0.18 
   18-19 years 4 (4) 1 (1)   
   20-29 years 45 (44) 54 (52)   
   30-39 years 29 (28) 31 (30)   
 40 
   40-49 years 16 (16) 15 (15)   
   50 and older 8 (8) 2 (2)   
   Median (Range) 30 (19-56) 28 (20-52) 0.11 
Donor race/ethnicity     0.46 
   Caucasian, non-Hispanic 92 (94) 92 (91)   
   African-American, non-Hispanic 0 2 (2)   
   Asian, non-Hispanic 2 (2) 4 (4)   
   Hispanic, Caucasian 1 (1) 0   
   Hispanic, race unknown 3 (3) 3 (3)   
   Unknown 4 (N/A) 2 (N/A)   
Year of transplant     0.61 
   2000 0 3 (3)   
   2001 2 (2) 4 (4)   
   2002 1 (1) 0   
   2003 1 (1) 3 (3)   
   2004 5 (5) 8 (8)   
   2005 15 (15) 11 (11)   
   2006 16 (16) 15 (15)   
   2007 17 (17) 17 (17)   
   2008 11 (11) 8 (8)   
   2009 14 (14) 9 (9)   
   2010 18 (18) 22 (21)   
   2011 2 (2) 3 (3)   
Follow-up among survivors, Months       
   N Eval 44 50   
   Median (Range) 60 (33-99) 61 (30-123) 0.93 
  
 
normalized IBD in each region is simulated from an all-by-all pairing of donors and 
recipients (excluding actual HLA-matched pairs). X and Y chromosomes were excluded 
from analysis. Removal of low-quality variants due to read misalignment resulted in 
small broken intervals in the ARD and MHC, explaining lower than expected genetic 
similarity for HLA-matched donor–recipient pairs within these regions. 
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Comparisons of donor-recipient variant call format files (Figure 3.2, Figure 3.3, Figure 
3.4; Supplementary Figure 3.2) was performed with RTG tools (Cleary et al. 2014) to 
generate patient-specific variants, which were functionally annotated with snpEff 
(Cingolani et al. 2012). Sex-mismatched pairs were considered as special cases with Y-
chromosome–specific variants in male recipients or genomic locations aligned to 
paralogous sites on the X chromosome. In all samples, missense and nonsense variants 
were mapped to their corresponding primary transcript and translated into amino acid 
sequences for proteasomal cleavage site prediction with netChop 3.1 (Keşmir et al. 
2002). MHC binding prediction was performed with netMHCpan 3.0 (M. Nielsen and 
Andreatta 2016) using patient HLA typing to determine MHC restriction. Ranked 
peptides were further annotated with minor allele frequencies from dbSNP (NCBI 
Resource Coordinators 2016) build 147. Acute GVHD usually affects the skin, liver, and 
gastrointestinal tract (Jacobsohn and Vogelsang 2007). While patient-specific MiHA 
expression is most informative, collecting these data requires invasive tissue biopsy 
specimens. Therefore, we opted to corroborate our results with public data from the 
Genotype-Tissue Expression Project (The GTEx Consortium 2015; GTEx Consortium 
2013; Keen and Moore 2015) using previously described methods (Kryuchkova-
Mostacci and Robinson-Rechavi 2017) to associate MiHAs with a measure of broad 
tissue-specific gene expression. The entire workflow is freely available at 
https://github.com/wwang-nmdp/MiHAIP.  
 
Visualization of X-Y paralogous regions (Figure 3.3A-C) were performed with manual 
curation using the BLAST-like alignment tool (Kent 2002). 
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Statistics 
P values were calculated using the  test for Table 3.1 and the Wilcoxon rank sum test 
with continuity correction for Figure 3.1, Figure 3.2A-C, Figure 3.3(A,D,E), and Figure 
3.4B. All other P values were calculated using hypergeometric tests with sample and 
population counts limited to patients with specified MHC restriction. Benjamini-Hochberg 
false discovery was applied to correct for multiple hypothesis testing in Supplementary 
Table 3.1. All tests were performed in R with default parameters. 
Results 
Donor-recipient matching extends beyond five HLA loci 
There is strong evidence that HLA-DPB1 T-cell epitope (TCE) matching correlates with 
allo-HCT outcome (Zino et al. 2004, 2007; Crocchiolo et al. 2009; Katharina 
Fleischhauer et al. 2012; Shaw et al. 2013; K. Fleischhauer et al. 2014; Pidala et al. 
2014). Generally speaking, mismatched alleles between donor and recipient may be 
benign (permissible) or alloreactive (nonpermissible) in either direction (graft versus host 
or host versus graft), with clinical consequences that include GVHD or rejection, 
respectively. Several methods are available to determine the direction and permissibility 
of HLA-DPB1 mismatching. Although pairs in this cohort were not explicitly matched at 
this locus at the time of transplant, a retrospective analysis revealed 16%, 60%, 68%, 
and 76% of donor–recipient pairs were matched by HLA-DPB1 allele, TCE permissibility 
(Zino et al. 2004), expression (Goyal et al. 2017), or functional distance (Crivello et al. 
2015), respectively (Supplementary Figure 3.1). This is consistent with baseline 
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likelihoods of finding HLA-DPB1 matches with productive 10/10 searches (Tram et al. 
2017). We found that HLA-DPB1 allele mismatching did not associate with acute GVHD 
(P = .92), whereas TCE mismatching did associate as expected (P = .038; 1-sided 
Fisher’s exact test), leaving 56 out of 102 acute GVHD cases (55%) unaccounted for by 
mismatching at 6 HLA loci. 
 
We hypothesized that HLA-matched unrelated donor-recipient pairs share genetic 
material outside the MHC. We used IBD inference (Browning and Browning 2013) to 
measure broad genomic similarity (see Methods), which revealed matching at the MHC 
regions as expected (Figure 3.1A). Overall, high rates of IBD were observed at the MHC, 
indicated by many outliers in randomized pairs, which can be attributed to very strong 
and recent natural selection acting upon these loci in the human population 
(Albrechtsen, Moltke, and Nielsen 2010). Genetic similarities extended further, albeit to a 
lesser degree, across chromosome 6 (Figure 3.1B) and genome-wide (P < 2.2e-16; 
Figure 3.1C). Unexpectedly, there was a single outlier in control experiments where 
donors and patients were randomly paired. This simulated pair shared 50% of their DNA, 
likely representing a parent-child or full siblings. To protect confidentiality, we did not 
analyze the relationship further. 
Autosomal MiHAs do not associate with acute GVHD 
To investigate patient-specific variation further, we developed an integrative 
bioinformatics workflow adapted from neoantigen discovery to perform comparative 
analysis of all HLA-matched donor-recipient pairs regardless of TCE permissibility 
(Supplementary Figure 3.2). 
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Figure 3.1 Frequency distributions of IBD segments normalized by the total lengths of regions of 
interest for the following: (A) MHC, including HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ; (B) 
chromosome 6; (C) and the whole genome. Horizontal black bars represent median values. 
Outliers (gray) are shown only for panel A (see text for details).  
 
The acute GVHD and non-GVHD groups displayed comparable numbers of missense 
variants (P = .32; Figure 3.2A) and known MiHAs (P = .80; Figure 3.2B) restricted with 
patient HLA (P = .76; Figure 3.2C). Ordering MHC-restricted MiHAs by log-ratio (Figure 
3.2D) revealed DPH1 (rs35394823) and LB-NISCH-1A (rs887515) as the lowest and 
highest ranking; however, no associations achieved statistical significance. Thus, we 
expanded our study to include pre-existing single-nuclear polymorphism microarray data 
from non-overlapping patient samples. With the addition of 988 HLA-matched donor–
recipient pairs (456 acute GVHD, 532 non-GVHD), no statistically significant 
associations were identified for 17 known MiHAs represented in both data sets 
(Supplementary Table 3.1). 
Y-chromosome–encoded variants associate with acute GVHD 
There were 89 sex-mismatched cases in our cohort (Figure 3.3A). Male recipients with 
female donors (F>M) were more likely to develop acute GVHD (78%) than male 
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recipients with male donors (52%, P < .02) Sequence analysis of the entire Y 
chromosome of F>M pairs identified only 6 missense variants (relative to the reference 
genome hg38) encoding a total of 9 variant peptides in 10 out of 21 recipients (48%) with 
acute GVHD. By contrast, the Y chromosomes of all 6 non-GVHD males matched the 
reference (Figure 3.3B). The variant peptides were confined to 4 genes: PCDH11Y, 
USP9Y, and UTY, which have reactive minor histocompatibility epitopes determined in 
vitro (Ofran et al. 2010; Vogt et al. 2000), and NLGN4Y, a neuroligin with unknown HCT 
significance. Except PCDH11Y, which is specific to the brain and heart, all genes have 
broad tissue expression (Supplementary Figure 3.3) and thus make qualified candidates 
for MiHA presentation in GVHD-affected tissues. Filtering by class I MHC restriction 
(Figure 3.3C) revealed several variant and reference peptides with strong affinity for their 
respective HLA allele in both the acute GVHD and non-GVHD groups (Figure 3.3D); 
however, there were significantly more predicted binders per GVHD male (P < .015; 
Figure 3.3E), suggesting a possible compound effect of multiple Y-linked MiHAs. HLA-
DPB1 alone did not explain the association, as 12 out of 21 F>M patients with acute 
GVHD (57%) were permissibly matched compared with 3 out of 5 without GVHD (60%) 
(P < .26; one patient was not typed at HLA-DBP1). 
Paralogous X-Y mismatching explains acute GVHD risk in male 
recipients with female donors 
Risk of chronic GVHD from allo-HCT is higher in male patients with female donors 
because of B-cell alloreactivity (Popli et al. 2014; Nakasone, Sahaf, and Miklos 2015; 
Miklos et al. 2005; Sahaf, Yang, and Arai 2013), which is detectable by antibody 
response that occurs after (Nakasone et al. 2015), but not before, transplant 
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Figure 3.2 Autosomal variants do not associate with GVHD. The number of patient-specific 
missense variants (A) as well as known unrestricted (B) and HLA-restricted (C) MiHAs is 
comparable in the acute GVHD and non-GVHD groups. (D) Known, HLA-restricted MiHAs 
ordered by log-odds ratio (acute GVHD to non-GVHD). SNP, single-nucleotide polymorphism.  
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Figure 3.3 Y-chromosome variants associate with acute GVHD. (A) Acute GVHD in sex-matched 
and sex-mismatched donor–recipient pairs, including a statistically significant association (star) in 
female-to-male (F>M) allogeneic stem cell transplant. Variants were identified in 4 genes 
(PCDH11Y, USP9Y, UTY, and NLGN4Y), which are displayed with approximate locations on the 
Y chromosome (B). Precise genomic coordinates and nucleotide and amino acid positions are 
tabulated, with variant residues shown in red. In some cases, alternative proteasomal cleavage 
prediction resulted in multiple peptides. (C-E) HLA-restricted affinity prediction for each color- 
coded peptide is shown for acute GVHD and non-GVHD patients (C) and summarized (D), with 
application of the recommended threshold for strong binders per male recipient (E). WT, wild-
type.  
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Figure 3.4 Paralogous X-Y mismatching explains acute GVHD risk in male recipients with female 
donors. (A) Six missense variants on the Y chromosome are exclusive to sex-mismatched male 
patients with acute GVHD. These variants correspond to 9 variant peptides, which are restricted 
to 4 genes. Genomic positions for PCDH11Y, USP9Y, UTY, and NLGN4Y are shown with dotted 
lines to paralogous genes on the X chromosome. Protein coding sequence alignments indicating 
identity matches (bars) and mismatches (dots) are shown for regions that contain individual 
variant residues (red) and peptides with high-affinity prediction (bold). Ending amino acid 
coordinates are given to the right of each sequence alignment. Two male-specific variants are 
named biallelic polymorphisms rs2524543 and rs2563389 with minor allele frequencies 46% and 
45%, respectively (red). Note the predicted cleavage sites (black triangles) created by coding 
variants in PCDH11Y and USP9Y. *For clarity, other alternative cleavage sites are not shown 
(see Figure 4 for details), and chromosome X is shown in reverse (39) orientation. (B) The 
number of predicted high-affinity binding peptides per patient in male-to-male allogeneic HCT 
recipients with and without acute GVHD.  
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Figure 3.5 MiHAs contribute to the therapeutic benefits and adverse effects of allo-HCT. In the 
donor-to-recipient direction, germline-encoded variant peptides (some of which may be presented 
by recipient HLA molecules) are expressed on both normal and tumor tissue and thus may 
contribute to GVT or graft-versus-host (GvH) effects. Tumor-specific somatic mutations that 
encode immunoreactive neoantigens contribute to GVT. In the recipient-to-donor direction, MiHAs 
may have host-versus-graft (HvG) effects in various clinical contexts leading to rejection in HCT 
and solid organ transplant (SOT) or miscarriage in pregnancy. Matching of HLAs reduces 
alloreactive responses from donor or host immune systems in transplantation settings. With cord 
blood HCT, HLA matching is usually performed at fewer (6) loci. This model does not fully 
illustrate the genomic and immunological complexities of graft predominance with multiple unit 
infusion. With haploidentical pairs, GvH effects in the recipient are controlled nongenetically with 
prophylaxis. Predictable patterns of germline inheritance determine match rates at HLA (4/8) and 
MiHAs (50%) with consequent effects on GVT. The presence and therapeutic benefit of 
neoantigens (because they are not heritable) are predicted to be independent of graft source.  
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(Nakasone et al. 2016). Results presented here extend risk in this patient segment to the 
acute form of GVHD by implicating male-specific variants in four genes. Although 
definitive clinical recommendations require confirmatory analysis, it is possible to 
investigate the genetic basis for risk in this cohort. 
 
PCDH11Y, USP9Y, UTY, and NLGN4Y have paralogs on the X chromosome (Lahn, 
Pearson, and Jegalian 2001) with 72%, 91%, 86%, and 24% amino acid identity, 
respectively. We mapped Y-encoded variant peptides from each male patient to 
paralogous sites on their female donor’s X chromosomes. All the variant peptides 
observed in males with acute GVHD mismatched corresponding sites (Figure 3.4A). By 
contrast, the 6 males without GVHD were X-Y matched at these sites, suggesting their 
donor-female immune systems were educated, and consequently non-alloreactive, to 
same-as-self peptides encoded at these positions. 
 
The only other category with increased (albeit statistically insignificant) risk of acute 
GVHD were male recipients with male donors (Figure 3.3A). Y-Y mismatching was 
explored as a possible explanation; however, the number of predicted high-affinity 
binders per patient (maximum 3) was comparable between recipients with and without 
acute GVHD in the M>M direction (P = .52; Figure 3.4B) and considerably lower than 
acute GVHD recipients in the F>M direction (maximum 12; Figure 3.3E). Furthermore, all 
female donors, regardless of recipient sex, lacked variants representing high-affinity 
binding peptides. These findings associate acute GVHD risk, with explanatory genetic 
factors, specifically in male patients with female donors, at least in this cohort. 
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Discussion 
Allo-HCT is a curative option for many disorders, yet side effects limit its widespread 
application. GVHD remains a principal barrier to more effective treatment and improved 
quality of life, but immune responses that contribute to therapeutic benefit and adverse 
events are physiologically coupled (Figure 3.5). In malignant conditions, tumor and 
normal cells are genetically distinct and analytically separable. In the context of allo-
HCT, immunoreactive peptides resulting from tumor-specific somatic mutations 
(neoantigens) may contribute specifically to GVL. On the other hand, the tissue-specific 
expression and immunogenicity of germline polymorphisms (MiHAs) determine their 
relative contributions to GVL or GVHD. As treatment options advance, it is important to 
precisely define genetic factors that affect (or do not affect) clinical outcomes.  
 
Despite research associating several autosomal MiHAs with clinical outcomes, none are 
routinely matched in allo-HCT. Target tissue expression partially determines the 
predominance of GVT or GVHD. For example, HA-2 (rs61739531) is expressed in cells 
of hematopoietic origin (Sellami et al. 2010) where there is evidence for GVL in AML with 
low risk of GVHD (Mutis et al. 1999). However, expression patterns are not wholly 
determinant. For example, ZAPHIR (rs2074071) associates with GVT, but not GVHD, in 
renal cell carcinoma patients receiving non-myleoablative allo-HCT (Broen et al. 2011). 
Similarly, other ubiquitously expressed MiHAs are associated with GVL in chronic 
myelogenous leukemia without evidence of GVHD, suggesting complex allo-reactivities 
from antigen processing, presentation, and costimulation (Griffioen et al. 2012). This is 
consistent with studies of cancer vaccines where therapeutic benefit results from the 
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synergistic effects of multiple cancer-specific neoepitopes combined with immune 
checkpoint blockade (Ott et al. 2017; Sahin et al. 2017). In all cases, MHC restriction is 
an important qualifier, but filtering patients by HLA reduces the number of samples 
available for retrospective analysis.  
 
Here, we analyzed common autosomal MiHAs with characterized HLA restriction in 
separate cohorts of 205 and 988 matched samples. We extended the capabilities of 
commonly used bioinformatics tools to aid comparative genomic analysis of donor–
recipient pairs, incorporating MHC matching and antigen restriction as well as HLA-
predicted binding affinity and tissue expression into a common workflow. This study was 
designed specifically to interrogate acute GVHD in AML patients who were in remission 
at the time of transplant. Consequently, leukemic cell counts were relatively low, and 
whole-genome sequences represented primarily germline polymorphism. Thus, 
bioinformatics analysis focused on MiHAs with broad tissue expression patterns. Future 
studies will apply these methods to patients with active disease, analyzing somatic 
variants (possible neoantigens) expressed in cells of hematopoietic origin within larger 
cohorts that are balanced for GVL-related outcomes including relapse.  
 
Our analysis of autosomes revealed no statistically significant associations with acute 
GVHD among individual MiHAs. These results confirm a recent genome-wide 
association study of unrelated allo-HCT where MHC mismatching outweighed other 
genetic factors as contributors to GVHD risk (Martin et al. 2017). As with neoantigens, it 
seems plausible that multiple recipient-specific variants contribute to GVHD; however, 
unlike clonal expansion of somatic mutations in cancer, population-genetic mechanisms 
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account for the co-occurrence of germline-encoded MiHAs. Indeed, there is evidence 
that arbitrary HLA-matched donor-recipient pairs may present thousands of MiHAs 
(Jameson-Lee et al. 2014), which have a cumulative effect on T-cell responses (Razzaq 
et al. 2016). Although MiHAs are individually common (with minor allele frequencies in 
our cohort ranging from 19% to 61%; Supplementary Table 3.1), alloreactive 
combinations may be rare, making it difficult to power case–control studies. Indeed, 
segmenting patients into subsets sharing	≥2 MiHAs lacked statistical power even when 
HLA restriction was limited to common alleles. Larger unrelated cohorts are necessary. 
Additionally, we plan comparable studies in related and haploidentical HCT pairs where 
shared donor-recipient haplotypes should reduce the number of MiHA combinations 
under consideration. These studies will also assess whether results reported here are 
relevant for patients receiving non-calcineurin-based GVHD prophylaxis.  
 
Our comprehensive analysis of sex-linked variation revealed multiple MiHAs encoded on 
the Y chromosome that associate with acute GVHD specifically in F>M allo-HCT 
patients. Relative to other chromosomes, the Y is better suited to case–control MiHA 
association studies, because it lacks population-scale genetic variability due to 
extremely low rates of diversifying recombination (Wilson Sayres, Lohmueller, and 
Nielsen 2014). Furthermore, since genetic and phenotypic sex are tightly coupled, it is 
easy to presegment genomic analysis into clinically weighted categories such as sex 
match or mismatch. Our limited cohort of primarily white patients suggests the majority 
of Y haplotypes in this population increase risk of acute GVHD for males with female 
donors. This is consistent with previous observations of increased chronic GVHD and 
lower relapse in F>M allo-HCT (Stern et al. 2008; Alois Gratwohl et al. 2009; A. Gratwohl 
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2012), adding a genetic basis for choosing HLA-matched male donors over nonparous 
females (Loren et al. 2006; Kollman et al. 2016). However, in cases where a female 
donor is otherwise the best option for male patients, results reported here may help 
select a more suitable match. 
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Chapter 4 Iterative feature selection method to 
discover predictive variables and interactions for 
high-dimensional transplant genomic data 2 
Abstract 
After allogeneic hematopoietic stem cell transplantation (allo-HCT), donor-derived 
immune cells can trigger devastating graft-versus-host disease (GVHD). The clinical 
effects of GVHD are well established; however, genetic mechanisms that contribute to 
the condition remain unclear. Candidate gene studies and genome-wide association 
studies have shown promising results, but they are limited to a few functionally derived 
genes and those with strong main effects. Transplant-related genomic studies examine 
two individuals simultaneously as a single case, which adds additional analytical 
challenges. In this study, we propose a hybrid feature selection algorithm, iterative 
Relief-based algorithm followed by a random forest (iRBA-RF), to reduce the SNPs from 
the original donor-recipient paired genotype data and select the most predictive SNP 
sets in association with the phenotypic outcome in question. The proposed method does 
not assume any main effect of the SNPs; instead, it takes into account the SNP 
interactions. We applied the iRBA-RF to a cohort (n=331) of acute myeloid leukemia 
                                               
2 This research has been submitted to a journal and undergoing a peer-review process. “Hu 
Huang, Cynthia Vierra-Green, Stephen Spellman, Caleb, Kennedy. Iterative feature selection 
method to discover predictive variables and interactions for high-dimensional transplant 
genomic data. (under review).” BioRxiv preprint DOI: https://doi.org/10.1101/605428. 
H.H. conceived the idea of machine learning application, designed and conducted the 
computational experiments, visualized and interpreted the results, and wrote the manuscript. 
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(AML) patients and their fully 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA-matched 
healthy unrelated donors and assessed two case-control scenarios: AML patients vs 
healthy donor as case vs control and acute GVHD group vs non-GVHD group as case 
vs control, respectively. The results show that iRBA-RF can efficiently reduce the size of 
SNPs set down to less than 0.05%. Moreover, the literature review showed that the 
selected SNPs appear functionally involved in the pathologic pathways of the phenotypic 
diseases in question, which may potentially explain the underlying mechanisms. This 
proposed method can effectively and efficiently analyze ultra-high dimensional genomic 
data and could help provide new insights into the development of transplant-related 
complications from a genomic perspective.  
 
Keywords: allogeneic stem cell transplantation; whole genome array genotype; acute 
graft-versus-host disease; acute myeloid leukemia; machine learning; feature selection; 
Relief-based algorithm (RBA); random forest 
Introduction 
Acute graft-versus-host disease (GVHD) is one of the major complications after HLA-
matching allogeneic hematopoietic stem cell transplantation (allo-HCT) that cause non-
relapse morbidity and mortality, affecting up to 40~60% of transplant patients and 
accounting for 20% of deaths after allogeneic HCT. It is an immunologically mediated 
complex disease. To date, genome-wide association studies (GWAS) and candidate 
gene studies have identified SNPs associated with acute GVHD, including SNPs that 
cause the genetic disparities between the donor and the patient, i.e., the minor 
histocompatibility antigen (MiHA) single nucleotide polymorphisms (SNPs)(Griffioen, van 
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Bergen, and Falkenburg 2016), and SNPs that modify gene functions (Petersdorf et al. 
2015). However, the genetic risks for acute GVHD outcome have not been well defined 
yet(Hansen et al. 2010). Most such studies have focused on single locus variants 
individually or a few candidate gene locations and tested them for association with acute 
GVHD. Unlike the assumptions of these studies, however, genes tend to interact within 
specific regulatory and functional pathways, contributing to the disease development.  
 
Next-generation sequencing technologies have enabled affordable high-throughput 
whole genome microarray genotyping and sequencing. These technologies pose 
multiple unique challenges in transplant-related genomic studies that need to be 
addressed and taken into consideration. First, each allo-HCT case involves in two 
individuals, the donor and the patient, both of whose genomes directly influence the 
transplant outcomes. Thus, the genomic association models should consider two 
genomes simultaneously as a single ‘sample,’ whereas, in common disease association 
studies, only either the donor or recipient genome is considered as a single sample. 
Second, the transplant-related outcomes are caused by the genomic disparities between 
donor and recipient with their synergistic interactions, and hence there is no inheritability 
of the diseases. Third, the allele frequencies may not play as much of an important role 
as in the common disease association studies; instead, the combinations and 
mismatches of donor-recipient (DR) pair genotypes may be more influential. Fourth, the 
cohorts in the transplant genomic studies are more heterogeneous and harder to control 
than in common disease studies. Each year, there are limited transplant cases due to 
the challenges of finding HLA-matching unrelated donors and hence it is harder to recruit 
groups that share most of the conditions. Furthermore, the cohort size usually is very 
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small compared to the common disease studies, and this also leads to the lack of 
publicly available transplant-related genomic databases. 
 
Alloimmune complications after stem cell transplantation, such as acute GVHD, not only 
involve immune responses to conventional exogenous antigens but also responses to 
alloantigens. The latter is unique to transplant cases. The major player in GVHD is the 
activated T cells that recognize and eliminate alloantigens. These T cell functions are 
influenced by the complex interactions between regulatory networks, pathways, 
extracellular environment and the unique conditions induced by transplantation 
procedures (Perkey and Maillard 2018). Thus, it is reasonable to assume that both 
donor’s and recipient’s genomes matter in the development of acute GVHD. However, 
most transplant-related outcome studies often focus on patients’ genomes, and very few 
studies have examined both HLA-matching donor and recipient genomes together 
(Martin et al. 2017). Here, we assume the donor’s genome as equal weight as the 
recipients and form a paired genotype encoding matrix from each transplant case. With 
a sufficiently large sample size and appropriate models, we can capture the interacting 
signals from the paired genome. 
 
Similar to the general whole-genome research in common disease studies as Moore and 
Ritchie outlined (Moore and Ritchie 2004), transplant-related genomic research also 
faces three major challenges. The first challenge is to identify meaningful genetic 
variants along with clinical characteristics that are susceptible to transplant-related 
complications. The genetic variants include SNPs, genes, or specific gene regions. As 
described above, transplant-related complications are mostly caused by the genetic 
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disparities between donor and recipient and the combination of their clinical and 
demographic characteristics (e.g., sex, age, race, and ethnicity), rather than the disease 
heritability. The second challenge is to build robust and powerful predictive models that 
take both genetic and demographic variables into account and output the probability of 
developing adverse transplant outcomes given a candidate graft characteristic. The 
predictive models will help facilitate effective and optimized donor search strategies with 
the best transplant outcomes. While the first two challenges are from statistical and 
machine learning aspects, the last challenge is to interpret the genetic variants and the 
predictive models from a biological perspective and further advance our understanding 
of the transplant-related complications. Biological functional interpretation will help 
optimize the donor selection process, improve the transplant outcomes and prevent 
transplant-related complications. It is the most important and difficult challenge and 
requires a deep understanding of human immunology as well as genetic regulatory 
mechanisms. Wet lab bench experiments would be the most effective way to validate the 
hypotheses but it would be too time-consuming and could become implausible if there 
are too many factors to control. It is one of the current leading translational 
bioinformatics research focus areas.  
 
Traditional logistic regression models, -test, odds-ratio are efficient and intuitive when 
finding simple linear relationships from a large-scale data set; however, they have limited 
power in modeling high-order non-linear relationships among variables, especially for 
ultra-high dimensional data. Whole genome microarray genotype data usually cover over 
500,000 base pairs of genetic variables and a majority of them may be considered as 
noise since they do not show any susceptibility to the diseases in question. Data mining 
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or machine learning techniques build models without any linearity assumptions on the 
data and can identify the high-order interactive relationship among variables. This is 
especially attractive to genomic data mining tasks. From a machine learning point of 
view, there are two main tasks in this context: 1) select the most informative variables 
from the over 1 million SNPs; 2) predict the disease risk from the selected variables 
using classifiers. From a clinical point of view, these selected variables should be 
interpretable. Unlike Mendelian diseases, transplant-related outcomes are influenced by 
non-linear interactions of multiple genes between donor and recipient. Transplant-related 
outcomes are more likely a joint effect of multi-factors rather than one single main effect 
factor. The attribute or feature interaction methods in machine learning seem more 
appropriate in this case. The data-mining methods can detect nonlinear relationships 
that traditional regression-based models cannot represent, and this is especially true for 
dealing with high-dimensional data. In addition, the data-mining algorithms may also 
uncover the interactions between variables other than their main effects. Applications of 
machine learning in detecting gene-gene interactions in genetic epidemiology are 
reviewed in (McKinney et al. 2006; Cordell 2009; Koo et al. 2013).  
 
The purpose of this study is to investigate the application of machine learning techniques 
in transplant genomics. More specifically, we propose a hybrid feature selection model 
(iRBA-RF) by incorporating the iterative Relief-based algorithms (iRBA) and a random 
Forest (RF).  
 
The rest of the paper is organized as follows. First, we define the transplant genomics 
and outcome association study in the machine learning context. Second, we briefly 
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review feature selection and classification models. Then we apply the proposed iRBA-
RF model to transplant cases to identify critical genetic factors. Lastly, we show the 
predictive results and provide a possible biological interpretation, as well as the 
applicability, limitations and future work.   
Methods 
Problem Definition  
In allo-HCT, histocompatibility of stem cells is the primary concern of graft selection, and 
there are many factors involved in the donor screening process. In this study, we 
retrospectively investigated 10 of 10 (HLA-A, -B, -C, -DRB1, -DQB1) HLA allele fully-
matched unrelated donor transplant cases, and explored the potential genetic variants 
that may influence the transplant outcomes. In addition to minor histocompatibility 
antigens (MiHAs), there are other genes involving in regulatory immunological pathways 
that are critical to the development of GVHD. In complex diseases, there is 
overwhelming evidence that non-additive synergistic effects of multiple genetic factors 
play an essential role in the development of the diseases. As described before, we 
consider the donor genome the same weight as the recipients. 
 
In order to investigate the applicability of the proposed model in the transplant related 
genomic studies, we assess the following two case-control scenarios: 1) Scenario 1 
(AML case-control): acute myeloid leukemia (AML) patients as case and their HLA-
matched healthy donors as the healthy control; 2) Scenario 2 (acute GVHD case-
control): the donor-recipient (DR) pairs where the patients developed the acute GVHD 
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symptoms as the case and the DR pairs where the patients did not show any adverse 
symptoms as the controls. 
 
The main difference between these two scenarios in the context of machine learning is 
how the genotypes are represented as a feature matrix. Scenario 1 is a common case-
control situation where each individual’s genotype vector is a single observation, and the 
AML disease condition is the phenotypic outcome to be predicted. In Scenario 2, an 
observation is defined as the combined genotype vectors of the recipient and the donor, 
where the length of the vector is doubled compared to Scenario 1. In addition to the DR 
genotypes, other clinical characteristics are also included in the model, such as the HLA 
typing and the donor-recipient sex-mismatch status.  
iRBA-RF: a hybrid feature selection model for detecting attribute 
interactions 
In bioinformatics, the “large p small n” problem is a common challenge, including when it 
comes to genomic association analysis. The most common problems in genomics data 
are 1) noisy data 2) heterogeneous data types, and 3) ultra-high dimensional feature 
space. In machine learning, the feature selection procedure is employed to avoid the 
“curse of dimensionality” for small samples with high dimensions (Friedman 1997; 
Domingos 1998, 1999). The objective of feature selection is to select the most relevant 
feature subset to achieve the best classification/prediction performance without losing 
the generalization power (accuracy, speed, and generalization). A strong feature 
relevance indicates the feature is necessary for the predictive model, while an irrelevant 
feature does not contribute to the predictability. In some cases, the presence of certain 
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features would decrease the predictability of the model, in which case they are 
considered as noise. For a formal theoretic derivation of feature relevance, interested 
readers may refer to (Bell and Wang 2000).  
 
Depending on the feature search strategy and the level of predictive classifier 
integration, there are three different categories of feature selection methods: filter, 
wrapper and embedded. Filter approaches are independent of classifiers; instead, they 
examine the intrinsic properties and relationship between the phenotype in question. 
Specifically, the information theoretic metrics, such as mutual information (Ding and 
Peng 2005; Peng, Long, and Ding 2005) and entropy/information gain (Xing et al. 2001; 
Eom and Zhang 2004), are popular options to measure the intrinsic properties. Since 
these approaches do not involve training a classifier, they are computationally fast and 
applicable to a large dataset. Detailed reviews of feature selection techniques in 
bioinformatics can be found in (Saeys, Inza, and Larrañaga 2007; Bolón-Canedo et al. 
2014).  
 
Since we are interested in interpretable variables that are linked to the phenotypes within 
a reasonable computation time, we adopt the filter-based approaches. More specifically, 
we propose a hybrid feature selection model that combines an iterative Relief-based 
algorithm and a random forest (iRBA-RF), to iteratively eliminate the irrelevant features 
and select the top-ranked features, respectively. In the next subsections, we describe 
the details of each algorithm.  
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Iterative RBA for variable elimination  
The Relief-based algorithms (RBAs) was inspired by instance-based learning (Aha, 
Kibler, and Albert 1991; Callan, Fawcett, and Rissland 1991), where it draws instances 
at random and iteratively compute and updates the weights of features based on their 
nearest neighbors and their phenotypes. The features that distinguish the selected 
instance from its neighbors of a different class get more weight. The original Relief 
algorithm only compares one nearest neighbor of each class, which is sensitive to noisy 
data and restricted to a binary classification problem. There have been many studies to 
address the limitations and improve the performance of the original Relief algorithm. The 
most widely used RBA is ReliefF (Kononenko 1994), which relies on the nearest k 
neighbors, instead of one. By comparing the entire vector of values across all attributes 
among neighbors, ReliefF can capture the attribute (feature) interactions and has gained 
popularity in data mining applications. Figure 4.1 shows an example of ReliefF on acute 
GVHD outcome data set with k =3 nearest neighbors in each class, respectively.  
 
However, ReliefF is not robust to noisy features where it cannot capture the correct 
signal. An improved ReliefF called Tuned ReliefF (TuRF)(Moore and White 2007) was 
proposed to iteratively remove features that have low-quality scores, in most cases are 
noisy features. More extended RBAs were later developed and applied in genomic data 
analysis, including Spatially Uniform ReliefF (SURF) (Greene et al. 2009), SURF* 
(Greene et al. 2010), SWRF* (Stokes and Visweswaran 2012), Multiple-Threshold* 
(MultiSURF*)(Granizo-Mackenzie and Moore 2013), and MultiSURF (Urbanowicz, Olson, 
et al. 2018). They use different strategies to select neighboring hits and misses 
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Figure 4.1 Illustration of ReliefF algorithm with 𝑘 = 3 nearest hits and misses, respectively, on 
transplant outcome data.  
 
Figure 4.2 Illustration of iRBA, adapted from (Urbanowicz, Meeker, et al. 2018).  
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and calculate their weights to improve sensitivities and computational efficiency. 
Furthermore, unlike the original Relief algorithm, these improved versions can handle 
incomplete data and extend to multi-class problems. For an in-depth review of RBA-
based feature selection methods, readers may refer to Urbanowicz et al. (Urbanowicz, 
Meeker, et al. 2018).  
 
In typical genomic association studies, there are over 500,000 SNPs to be examined. 
Especially in the context of transplantation, donor-recipient pair genotypes may include 
over 1 million SNPs. This poses a challenge in computational efficiency. For such ultra-
high dimensional genomic data, iterative and efficient approaches that are wrapped 
around and integrated into the above core RBAs are recommended. VLSReliefF 
(Eppstein and Haake 2008) algorithm is reported to be able to detect feature interactions 
in a very large feature space both efficiently and accurately. The main idea is to 
randomly select s subsets of the feature set with Ns features and individually apply 
ReliefF to each group to calculate local feature weights. The global weights of each 
feature are the maximum value of the local feature weights among the subsets. In this 
study, we follow the framework of VSLReliefF and repeat the process multiple times to 
remove low-quality features iteratively, as shown in Figure 4.2. Instead of ReliefF, here 
we choose MultiSURF as the core RBA since it has shown to outperform in multi-way 
interaction detection as well as various associations, compared to the other RBA 
algorithms (Urbanowicz, Olson, et al. 2018). 
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Random forests for feature importance ranking and variance 
selection 
Random forests (RF) are ensembles of tree-structured classifiers that are constructed in 
the following random fashion: each tree is grown using a bootstrap sample, i.e., 
aggregated sampling with replacement, of original training set and a randomly chosen 
subset of features and a majority voting scheme to ensemble individual trees, as 
illustrated in Figure 4.3 (Breiman 2001). Instead of using the whole set of a training set, 
each tree is trained on the bootstrapped sample set, and the rest samples are used as a 
validation set to estimate the tree’s classification error. This validation set is called the 
out-of-bag (OOB) samples. The OOB scheme is used to monitor the generalization 
error, strength, and correlation of trees in the forests, as well as the variable importance. 
As more trees added to the RF, it is guaranteed to converge with a limited generalization 
error and does not suffer from overfitting problem due to the Law of Large Numbers 
(Breiman 2001).  
 
In addition to its effective predictive ability, RFs also measure the importance of the 
variables in terms of their relevance to the phenotypic outcome. This function has shown 
great potential in genome-wide association studies and bioinformatic applications due to 
its effectiveness and potential interpretability. The original RF measures the feature 
importance using two different metrics. 
 
The first variance importance metric is called Gini impurity index-based feature 
importance (GIFI). At a node in a tree, the objective is to reduce the class ambiguity as  
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(a) 
 
(b)  
Figure 4.3 Diagram of single decision tree and the random forests. (a) a single decision tree in 
the forest; (b) Random Forest classifying transplant outcome from the donor-recipient pair 
genotypes. 
the tree grows and the split at a node is determined by the feature that reduces the class 
ambiguity the most when the sample passes down the split. In RF, the impurity of splits 
is measured by the Gini impurity index (Breiman et al. 1984), defined as follows: 
suppose at a node ,  observations are trained using feature set 𝑅' =
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{𝑓'*, 𝑓',,… , 𝑓'.}. Write  to denote each observation, where  has 𝑑-dimensional 
features and  is the corresponding outcome label of  possible classes, 
. The frequency of class  at node  is defined as  
, 
where ∑ 𝑝'3435* = 1. The final class of the observation at the node is determined as argmax3 𝑝'3, i.e., the majority class in the node . For binary classification ( ), the 
Gini impurity index is defined as 
 
 
In our case-control cases, there are two classes: AML patient as 1 and healthy donor as 
0 for scenario 1; or acute GVHD group as 1 and non-acute GVHD group as 0 for 
scenario 2. In both cases, the Gini impurity index is 
 
where  and  are the probabilities of the two classes mentioned above, respectively, 
and .  
 
The GIFI score of a feature in a tree is calculated as the sum of the Gini impurity 
decrease from a parent node to its children nodes over all nodes in the tree. The GIFI 
score of a feature in the RF is then defined as the sum (or average) of the Gini 
importance values among all trees in the forest.  
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The second feature importance is based on the feature’s predictability. After estimating 
the OOB prediction error during the training phase, the feature values in the OOB data 
set are randomly permuted and fed into the trained RF. The difference between the OOB 
prediction error and the permuted prediction error is defined as the prediction-based 
feature importance. If this value is a large positive value, the corresponding feature has 
high predictability and is favored high in the ranking; whereas negative or zero values 
indicate the features are not predictive and thus are discarded in ranking.  
 
It has been shown that both of these metrics suffer a certain degree of selection bias 
when ranking features. The GIFI favors the features with many possible split points, i.e., 
categorical variables with many categories or continuous variable (Strobl et al. 2007). In 
genomic variance selection, it tends to be in favor of SNPs with high minor allele 
frequencies (MAF) (Nicodemus 2011; Boulesteix et al. 2012). Many studies have 
proposed correction methods to eliminate bias. Altmann et al. (Altmann et al. 2010) 
proposed to permute the response (phenotypic outcome) to calculate the null importance 
distribution while preserving the relationships between features. The algorithm is shown 
to reduce the feature selection bias induced by the GIFI but also provides the 
significance level P-values for each feature. Later, Janitza et al. (Janitza, Celik, and 
Boulesteix 2016) proposed an alternative approach to improve the computational speed 
while correcting the feature selection bias and providing the P-values for each feature. 
Nembrini et al. (Nembrini, König, and Wright 2018) provided a unified framework with a 
corrected impurity importance measure (AIR) to calculate the GIFI fast and they claimed 
that AIR outperforms the previous approaches in terms of computational performance 
and statistical power. All these bias correction methods have been incorporated and 
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implemented in the R package ranger (Wright and Ziegler 2017), and the Altmann-
corrected GIFI is adopted in this study.   
  
The prediction error-based feature importance (PEFI) does not have these issues; 
however, it tends to favor the features that locate closer to the root node since they tend 
to affect the prediction accuracy of a larger set of observations and the permutation-
based importance favors these variables (Strobl et al. 2007). A modified PEFI was 
proposed by Ishwaran (Ishwaran 2007), where it follows the same procedure as in the 
original RF, except instead of permuting the features in the out-of-bag data and test on 
the trained trees from the in-bag data, here the trees are randomized by using left-right 
random daughter assignment at each of the features. When a case is dropped down to 
the node with the feature in question, the left and the right daughter nodes of the 
following lower trees are chosen randomly with the same probability to till it reaches the 
leaf node. This procedure promotes the poor leaf node values for cases that pass 
through the nodes that split on the feature.  
 
The predictability of the selected feature set is assessed by using OOB samples with the 
overall classification error, area under the receiver operating characteristic curve (AUC), 
and the normalized Brier score defined by Ishwarn and Lu(Ishwaran and Lu 2018). Brier 
score is more stable than AUC when assessing the classifier performance. A value of 
100 normalized Brier score indicates random guessing and 0 being a perfect classifier.  
 
Figure 4.4 shows the proposed iRBA-RF feature selection model. During the first stage, 
noise and phenotypically irrelevant features are removed through the iRBA using  
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Figure 4.4 Illustration of iRBA-RF feature selection model 
MultiSURF as its core RBA. By removing the lowest ranked features, it retains the multi-
way interaction relationships between features from MultiSURF. The refined feature set 
is then fed into the RF model in the second stage. The RF then train models and rank 
the features through GIFI and/or PEFI metrics. In this study, we implemented the model 
by incorporating the scikit-rebate library written in Python (Urbanowicz, Olson, et al. 
2018) (available at https://github.com/EpistasisLab/scikit-rebate) and two random forest 
R packages, ranger (Wright and Ziegler 2017) and randomForestSRC (Ishwaran et 
al. 2008; Ishwaran and Lu 2018).  
Data Collection and Preprocessing 
A retrospective cohort of blood cancer patients and their HLA matching donors have 
been selected in this study. The microarray genotype data collection and primary 
analysis have been described in (Madbouly et al. 2017). In order to reduce the bias 
induced by disease types and the reference population, we chose AML patients and 
their transplant cases and used the original genotypes without imputation. After data 
quality control [Supplementary Material 4.7], 331 transplant cases (662 individuals in 
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total) of AML patients and HLA matching donors with 630,793 genotyped autosomal 
SNPs were included in this study. SNPs from the sex chromosome were excluded from 
this study; however, sex-mismatch conditions were considered as clinical characteristics 
in Scenario 2 acute GVHD case-control context. 
 
As described in the Methods section, we investigated the iRBA-RF model in two 
scenarios. In Scenario 1, the formatted genotype matrix has a size of 662×630,793 and 
the AML disease status as its target label; in Scenario 2, the formatted genotype matrix 
has a size of 331×1,261,586 and the acute GVHD status as the target label. 
Results 
Scenario 1: AML case-control experiment 
The original 630,793 SNPs were reduced to 200 SNPs through the iRBA-RF and they 
were further reduced to 176 SNPs and 164 SNPs using GIFI and PEFI, respectively. 
Table 4.1 shows the top 30 SNPs ranked by the GIFI scores with their significance P-
values. Of the 176 GIFI-based SNPs, 103 SNPs showed statistically significant scores at 
the confidence level . The full list for the 200 SNPs can be found in the 
Supplementary Table 4.1.   
 
The PEFI scores are further assessed through the delete-d Jackknife subsampling 
scheme as proposed in (Ishwaran and Lu 2018). Figure 4.5 illustrates the 95% 
asymptotic normal confidence intervals for the top 50 SNPs ranked by the median PEFI 
scores. For a full list of features by PEFI, please refer to Supplementary Table 4.2. 
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Compared to the SNPs listed in Table 4.1, 9 SNPs (rs2694642 (USP34), rs928770 
(KCNJ15),  rs10936248, rs2293836 (NRXN3), rs6915644 (EYS), rs1173099, rs788871, 
rs17329514,  rs675992) are ranked in the top 30 in both cases, whereas 3 SNPs 
(rs10002187, rs6106323, rs1365342) from Table 4.1 ranked between 31 and 50 in 
Figure 4.5.  
Table 4.1 Top 30 SNPs linked to AML, which are ranked by the Gini impurity importance using 
the bias-corrected Altmann-GIFI. For illustration purpose, here lists the top 30 SNPs out 200 
SNPs from the proposed feature selection model. 
Ran
k 
Marker CHR:POS Gene(s) Maj
or 
Minor MAF Import
ance 
score 
p-
values 
1 rs2694642 chr2:61369045 USP34 A G 0.315 1.669 0.010 
2 rs928770 chr21:38265545 KCNJ15 C T 0.287 0.932 0.010 
3 rs10936248 chr3:161818648  C T 0.383 0.854 0.020 
4 rs4698732 chr4:14336718  C T 0.442 0.832 0.010 
5 rs4692262 chr4:27923209 LOC1053
74552* 
C A 0.372 0.770 0.040 
6 rs11869908 chr17:72674911 SLC39A1
1 
G T 0.210 0.768 0.010 
7 rs7718156 chr5:172669363 NEURL1
B 
C A 0.321 0.719 0.010 
8 rs2293836 chr14:79840947 NRXN3 T C 0.112 0.694 0.010 
9 rs6915644 chr6:65106919 EYS G A 0.397 0.692 0.010 
10 rs10002187 chr4:149994262 DCLK2** G A 0.190 0.689 0.010 
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11 rs749773 chr2:165877228 TTC21B T C 0.199 0.644 0.020 
12 rs285206 chr20:43667902 MYBL2 T C 0.202 0.605 0.010 
13 rs10926025 chr1:239949314 LOC1053
73224 
C T 0.298 0.597 0.010 
14 rs12675334 chr8:83887031  A G 0.396 0.587 0.020 
15 rs9819506 chr3:172452314 GHSR*; 
BZW1P1*
*; 
TNFSF10
***; 
FNDC38*
** 
C T 0.427 0.578 0.030 
16 rs6106323 chr20:2169032 STK35**; 
LOC1053
72502** 
G A 0.257 0.574 0.010 
17 rs2914290 chr5:7629643 ADCY2 C T 0.181 0.565 0.010 
18 rs1365342 chr4:37097911 LOC1019
28721 
G A 0.329 0.564 0.040 
19 rs1173099 chr9:90679392 DIRAS2**
; 
OR7E109
P*** 
T G 0.260 0.556 0.010 
20 rs2222514 chr7:123206473 SLC13A*; 
LYPLA1P
1** 
A G 0.432 0.548 0.010 
21 rs12714359 chr2:2603252 LOC1053
73389***; 
LOC1079
85839*** 
A G 0.367 0.548 0.020 
22 rs2185591 chr20:43133279 PTPRT C A 0.423 0.542 0.020 
23 rs788871 chr1:30591356 MATN1**
* 
T C 0.474 0.528 0.030 
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24 rs17329514 chr18:71998994 LOC1027
25148***; 
LOC1053
72189*** 
A G 0.101 0.522 0.010 
25 rs41135 chr5:96830323 ERAP1 G A 0.369 0.519 0.020 
26 rs428148 chr2:70583509 TGFA*; 
ADD2*** 
C T 0.298 0.518 0.030 
27 rs10794031 chr10:12587675
1 
DHX32 A G 0.439 0.517 0.020 
28 rs725856 chr4:39746658 UBE2K A G 0.124 0.510 0.010 
29 rs675992 chr1:17888266 ACTL8*** A G 0.255 0.492 0.040 
30 rs2025009 chr14:68376888 RAD51B C G 0.476 0.491 0.020 
*: genes that are within 10 kb range of upstream or downstream from the marker 
**: genes that are outside 10 kb but within 50 kb range from the marker 
***: genes that are outside 50 kb but within 100 kb range from the marker 
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Figure 4.5 Delete-d Jackknife 95% asymptotic normal confidence intervals for the top 50 SNPs in 
the AML case-control scenario. The large positive variance importance values indicate the high 
predictability of the features, whereas zero and negative values suggest noise variables. 
Scenario 2: aGVHD case-control 
In the case of acute GVHD, the genotype matrix has twice as many dimensions as 
Scenario 1, since the donor and recipient genotypes were concatenated in the same 
 78 
vector for each case. The original genotype matrix has a total of 1,261,586 SNPs, and 
after the iRBA-RF, the number was reduced to 400 SNPs. The classical HLA typing 
(HLA-A, -B, -C, -DQB1, -DRB1) and DR pair sex mismatch status are major factors that 
influence the transplant outcome, and hence these two types of variables were added to 
the reduced genotype matrix before RF feature ranking. A total of 411 variables (400 
SNPs, 10 HLA gene typing, 1 sex mismatch status) were ranked through the RF using 
GIFI and PEFI metrics, respectively.  
 
342 out of 411 variables were selected through GIFI scores, only 124 of which showed 
statistically significant scores at the confidence level . Top 30 variables by GIFI 
is listed in Table 4.2, and the full list can be found in Supplementary Table 4.3. Similar to 
Scenario 1, PEFI scores are assessed through delete-d jackknife subsampling 
procedure and estimated the 95% asymptotic normal confidence interval. 297 variables 
were selected through PEFI scores, top 50 of which are shown in Figure 4.6. The full list 
of PEFI features can be found in Supplementary Table 4.4.  
 
Compared to GIFI features in Table 4.2, 6 SNPs [rs10936748 (LOC105374224), 
rs3818283 (TEK), rs17161332 (SGCZ), rs17236893 (LOC101928583), rs10974006, 
rs2868956] are ranked in the top 30 in both cases, whereas 4 SNPs [rs1341852 
(LOC105370228), rs11160228, rs4863533, rs504371 (C6orf118)] from Table 4.2 ranked 
between 31 and 50 in Figure 4.6. 
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Table 4.2 Top 30 variables linked to acute GVHD, which are ranked by the bias-corrected 
Altmann-GIFI. For illustration purposes, here lists the top 30 variables out 411 SNPs from the 
iterative feature selection model.  
Ran
k 
Marker CHR: 
POS 
Gene(s) Maj
or 
Min
or 
MAF Source Importanc
e score 
P-
value 
1 rs109367
48 
chr3:17
328359
7 
LOC10537
4224 
T G 0.151 recipien
t 
0.562 0.020 
2 rs238992
3 
chr4:11
981054
2 
LINC0136
5** 
A G 0.246 donor 0.507 0.010 
3 rs171720
94 
chr7:42
622588 
LOC10537
5251 
G A 0.435 recipien
t 
0.474 0.010 
4 rs381828
3 
chr9:27
169126 
TEK C T 0.252 recipien
t 
0.473 0.010 
5 rs426232
2 
chr8:14
839455 
SGCZ G T 0.244 donor 0.472 0.020 
6 rs141026
7 
chr13:9
761411
1 
LOC10537
0324 
A C 0.306 donor 0.471 0.010 
7 rs171613
32 
chr7:78
675562 
MAGI2 T C 0.069 recipien
t 
0.417 0.010 
8 rs134185
2 
chr13:6
035065
3 
LOC10537
0228 
A G 0.449 recipien
t 
0.416 0.010 
9 rs794083
5 
chr11:3
244721 
MPGPRE*
* 
T C 0.140 recipien
t 
0.408 0.010 
10 rs718728
9 
chr16:6
793397
5 
PSMB10*; 
CTRL*; 
PSKH1*; 
LCAT*; 
SLC12A4* 
A C 0.320 donor 0.406 0.010 
11 rs463867
0 
chr18:2
770118
3 
LOC10537
2042*** 
A C 0.174 recipien
t 
0.404 0.010 
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12 rs354843 chr4:14
126765
0 
ZNF330**; 
RNF150**
* 
T C 0.269 donor 0.400 0.010 
13 rs719910 chr7:42
722647 
LINC0144
8** 
T C 0.399 recipien
t 
0.395 0.010 
14 rs646155
1 
chr7:21
312333 
 G A 0.383 recipien
t 
0.391 0.010 
15 rs172368
93 
chr3:17
074583
3 
LOC10192
8583 
A G 0.095 recipien
t 
0.367 0.010 
16 rs109740
06 
chr9:38
738297 
 G T 0.257 recipien
t 
0.364 0.020 
17 rs273592 chr11:3
085730
2 
LOC10798
4419 
A G 0.482 recipien
t 
0.361 0.010 
18 rs248195
5 
chr13:2
800944
4 
FLT3 G A 0.378 donor 0.360 0.010 
19 rs227130 chr20:8
452312 
PLCB1 G A 0.370 recipien
t 
0.350 0.020 
20 rs111602
28 
chr14:9
505180
6 
DICER1** G A 0.242 recipien
t 
0.336 0.010 
21 rs486353
3 
chr4:13
799240
0 
LOC10798
6315**; 
LOC10537
7447**; 
LINC0061
6**; 
SLC7A11*
** 
G A 0.270 recipien
t 
0.333 0.010 
22 rs286895
6 
chr19:2
832051
1 
LOC10798
5269** 
T C 0.235 recipien
t 
0.329 0.020 
23 rs130356
54 
chr2:13
989471
6 
 T C 0.182 recipien
t 
0.328 0.020 
24 rs509012 chr13:2
172052
FGF9** G A 0.225 donor 0.316 0.020 
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4 
25 rs105039
60 
chr8:34
340069 
RPL10AP
3*** 
A C 0.181 donor 0.314 0.010 
26 rs122035
92 
chr6:39
6321 
IRF4 C T 0.037 recipien
t 
0.304 0.010 
27 rs127635
63 
chr10:1
298997
1 
CCDC3 G A 0.220 recipien
t 
0.301 0.010 
28 rs468536
6 
chr3:16
614824 
DAZL* A G 0.445 donor 0.301 0.030 
29 rs504371 chr6:16
531056
3 
C6orf118; 
LOC10537
8113 
G T 0.431 recipien
t 
0.298 0.010 
30 rs216149
5 
chr5:10
375044
6 
LOC10537
9107 
C T 0.313 recipien
t 
0.297 0.010 
*: genes that are within 10 kb range of upstream or downstream from the marker 
**: genes that are outside 10 kb but within 50 kb range from the marker 
***: genes that are outside 50 kb but within 100 kb range from the marker 
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Figure 4.6 Delete-d Jackknife 95% asymptotic normal confidence intervals for the top 50 SNPs in 
the acute GHVD case-control scenario. The large positive variance importance values indicate 
the high predictability of the features, whereas zero and negative values suggest noise variables. 
‘r_’ indicates SNPs from recipients, while ‘d_’ for SNPs from donors. 
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Discussions 
Ideally, the features that are selected by iRBA-RF have the best predictability on the 
phenotypic outcomes and the related gene regions are actively involved in the pathways 
of the diseases in question. To assess the results, we first examined the predictability of 
the selected feature sets by comparing the classification performance to a random set of 
features with the same size. The classification performance was examined in three 
criteria: the normalized Brier score where a score of 100 indicates a random guess and 
the lower, the better classifier performance, the AUC, and the overall OOB error rate. 
Figure 4.7 shows the comparison among different feature sets. The random feature sets 
(Random200/Random400) were selected 1000 times, while the rest feature groups were 
trained and tested on OOB samples 1000 times. The selected features through iRBA-RF 
(Top200/Top400, GIFI, PEFI) in both scenarios show significantly superior classification 
performance in all three criteria (p < 2.2e-16). Within the selected groups 
(Top200/Top400, GIFI, PEFI), the pairwise t-tests showed a significant difference 
between each group using all three criteria (p < 0.001), except for the Brier scores 
between Top200 and GIFI groups. As shown in Figure 4.7, the classifiers using the 
PEFI-based feature sets generally showed better predictive performance, and this is 
mainly because PEFI-based features are ranked based on the classifier’s performance.  
 
From the functional point of view, the top-ranked features are not random and evidence 
can be found in the literature. In Scenario 1, multiple SNPs among the selected 200 
SNPs are from the following functional gene groups that are reported to be linked to 
AML (Cancer Genome Atlas Research Network et al. 2013; Peker 2018). These gene  
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(a) Scenario 1: AML case-control 
 
(b) Scenario 2: aGVHD vs non-GVHD 
Figure 4.7 (a) Scenario 1: AML case control.  (b) Scenario 2: aGVHD vs non-GVHD. Comparison 
of four different sets of features: (1) Random200 (or Random400): 200 (or 400) features randomly 
selected from the original feature set. (2) Top200 (or Top400): top ranking 200 (or 400) features 
selected by the iRBA-RF algorithm (3) GIFI: 176 (or 342) SNPs out of the selected 200 (or 400) 
SNPs using the GIFI score, (4) PEFI: 164 (or 297) features out of the selected 200 (or 400) SNPs 
using the PEFI score. Each feature sets were trained 1000 times and evaluated by the 
normalized Brier scores, AUC and overall error rate of OOB samples, respectively.  
groups include spliceosome (rs10794031, rs3205166), cohesin complex (rs2025009), 
epigenetic modifiers (rs1987193), serine/threonine kinase (rs10002187, rs994502, 
rs13000880), protein tyrosine phosphatases (rs2185591) and other myeloid transcription 
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factors (rs285206). Most of these SNPs didn’t show significant importance scores, 
however, SLC39A11 (rs11869908), MYBL2 (rs285206), PTPRT (rs2185591), DHX32 
(rs10794031), RAD15B (rs2025009) are ranked the top 30 GIFI with 𝑝 < 0.05.  
 
SLC39A11 (rs11869908), also known as ZIP11, is a zinc transporter gene that has been 
reported to be linked to multiple cancers (Pan et al. 2017). Specifically, a high 
expression of ZIP4 and low expression of ZIP11 are significantly associated with the 
higher grade of Glioma (Kang et al. 2015). In addition, mutations in IDH1 is reported to 
be highly correlated with higher expression of ZIP11, suggesting a possible synergistic 
interaction between IDH1 and ZIP11 (Kang et al. 2015). MYBL2 (rs285206) has an 
essential role in cell cycle progression, cell survival, and cell differentiation, and is found 
to be overexpressed in multiple cancer cases (Musa et al. 2017). Overexpression of 
MYBL2 is suggested to have a prognostic value for disease-free survival and cumulative 
incidence of remission for AML patients (Fuster et al. 2013; Musa et al. 2017). PTPRT 
(rs2185591) encodes cellular signaling proteins that regulate cell growth, differentiation, 
and oncogenic transformation and is reported to be in the genetic interaction network of 
AML mutational landscape (J. W. Lee et al. 2007; Becker et al. 2014; Ibáñez et al. 
2016). DHX32 is an RNA helicase that is reported to associate with the acute 
lymphoblastic leukemia (Abdelhaleem 2002, 2005). Notably, its dysregulation is believed 
to contribute to carcinogenesis (Alli, Ho, and Abdelhaleem 2005). RAD51B (rs2025009) 
encodes one of the RAD51 paralogs that participate in DNA repair, and the 
polymorphisms in the gene and the gene inactivation through chromosome translocation 
have been demonstrated to be linked to AML, breast cancer, head and neck cancer 
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(Nowacka-Zawisza et al. 2015; Miao et al. 2015; Rollinson et al. 2007; Cheng et al. 
2014).  
 
Other genes ranked high in the list have also shown evidence of roles in AML linked 
pathways. For instance, the top-ranked gene USP34 (rs2694642) is reported to regulate 
the levels of axin and stabilize beta-catenin and further modulate Wnt signaling pathway 
positively (Lui et al. 2011). Wnt/β-catenin pathway has shown to be essential in AML for 
leukemia stem cells to develop and thus allow malignant progression (Y. Wang et al. 
2010; Müller-Tidow et al. 2004; Holland et al. 2013; Tickenbrock et al. 2008; Reya et al. 
2003; Reya and Clevers 2005). KCNJ15 (rs928770) encodes potassium inwardly-
rectifying channel on the cell membrane and is reportedly a susceptible gene for Type 2 
diabetes(Okamoto et al. 2010, 2012) and linked to the hematological traits and clinical 
features of Down syndrome (Felipe et al. 2006; J.-B. Lee et al. 2016; Canzonetta et al. 
2012). NEURL1B is a paralog of NEURL1, and the deletion of this gene region has been 
linked to adult de novo AML (Cancer Genome Atlas Research Network et al. 2013). 
 
In the case of acute GVHD, most of the top-ranked SNPs do not lie in a gene region; 
however, they are within 50 kb range of downstream or upstream of the coding genes. 
Interestingly, multiple gene regions from donors are ranked high in both GIFI- and PEFI-
based feature set, suggesting the potential role of genetic polymorphisms from graft 
stem cells in the transplant outcomes. Genes that are linked to abnormalities of skin and 
the gastrointestinal (GI) tract are also selected by the iRBA-RF algorithm, all of which 
are the main symptoms of acute GVHD.  
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Notably, rs7187289 (donor) is located on chromosome 16q22.1, where five genes 
(PSMB10, CTRL, PSKH1, LCAT, SLC12A4) tightly clustered together(Larsen et al. 
1993). It is in the upstream of PSMB10, an immunoproteasome subunit that plays a vital 
role in major histocompatibility complex (MHC) class I restricted antigen processing and 
presentation(Nagata et al. 2003), T-cell polarization and differentiation, and cytokine 
production by macrophages(Kimura et al. 2015). Hence, PSMB10 is believed to involve 
in the development of inflammatory autoimmune diseases and hematologic 
malignancies and to be a marker of cell damage and immunological activity (Csizmar, 
Kim, and Sachs 2016). In renal transplantation, it has recently reported being associated 
with chronic antibody-mediated rejection (AMR) and posed as a potential intragraft and 
peripheral blood marker of acute rejection (Ashton-Chess et al. 2010; Iwase et al. 2011). 
The impairment of immunoproteasome subunits is critical for malignant cells to escape 
immune recognition, suggesting its possible role in the graft-versus-tumor effect after 
allo-HCT. LCAT is secreted by the liver and generally believed to maintain the 
unesterified cholesterol gradient between peripheral cells and high-density lipoprotein 
(HDL)(Asztalos et al. 2007). SLC12A4 encodes a human potassium chloride 
cotransporter 1 (KCC1) (Zhou et al. 2004), and the dysfunction of the membrane ion 
channels has been reported to link to several diseases, like sickle cell disease (Kato et 
al. 2018). 
 
Several gene regions in the list have direct roles in the signs of acute GVHD in the GI 
tract. CTRL is a chymotrypsin-like protease expressed in the pancreas and secreted in 
pancreatic juice (Whitcomb and Lowe 2007) and is well known to be downregulated in 
pancreatic cancer (Laurell et al. 2006). PSKH1 protein is mainly found in Golgi 
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apparatus, endoplasmic reticulum (ER), nucleus, cell membrane, cytoskeleton (G. Brede 
et al. 2000) and believed to play a role in intranuclear serine/arginine-rich domain (SR 
protein) trafficking and pre-mRNA processing (Gaute Brede, Solheim, and Prydz 2002). 
A recent study suggested it possibly linked to the pathogenesis of Crohn’s disease 
(Iborra et al. 2018). MAGI2 (rs17161332) encodes a scaffolding protein that involved in 
epithelial integrity, and studies have shown that the genetic variation in MAGI2 is linked 
to the inflammatory bowel disease (IBD), i.e., ulcerative colitis and Crohn’s disease 
(McGovern et al. 2009). Moreover, IRF4 (rs12203592) controls TH2 (type 2 T helper cell) 
responses and intestinal Th17 cell differentiation, mucosal cytokine IL-17 regulation, 
suggesting a central of IRF4 in immune regulation in the gut (Messmann et al. 2015; 
Cretney et al. 2011; Zheng et al. 2009; Huber et al. 2008; Persson et al. 2013; Schlitzer 
et al. 2013).  
 
The risk of getting a secondary solid cancer following allo-HCT is substantially higher 
than in general population, and the risk factors have been well documented (Curtis et al. 
1997; Inamoto et al. 2015; Tichelli et al. 2018). Melanoma, breast cancer, thyroid cancer, 
prostate cancer, and cervix cancer are the most frequently occurring cancer types after 
allo-HCT in the recipient’s later life. The genes that were selected in this study have 
evidence to link to the cancer progression and may be able to explain the incidents. The 
feature sets after iRBA-RF include multiple genes that play critical roles in the 
progression of carcinogenesis. For example, SGCZ (rs4262322) encodes a protein that 
plays a role in maintaining cell membrane stability and have been reported its role linked 
to cancer development and progression (Chi, Murphy, and Hu 2018). DICER1 
(rs11160228) encodes essential proteins for a micro-RNA processing pathway and plays 
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a central role in epigenetic modulation of gene expression, and downregulation of 
DICER1 expression has been reported to be linked to a wide range of cancer 
types(Bahubeshi, Tischkowitz, and Foulkes 2011; Radom-Aizik et al. 2010). 
 
A few leukocyte-specific genes, such as TEK, FLT3, and PLCB1 are also ranked high in 
the list. TEK (rs3818283) encodes angiopoietin-1 receptor that is critical to the induction 
and growth of new blood vessels and influence tumor growth. It has been reported that 
mutations in TEK are linked to AML suggesting its essential role in leukemogenesis 
depending on an uncharacterized cellular context (Tyner et al. 2009; De Palma et al. 
2005). A more recent study demonstrated that angiogenesis precedes leukocyte 
infiltration during inflammation suggesting the essential involvement of angiogenesis in 
the initiation of inflammatory diseases, such as acute GVHD and IBD (Riesner et al. 
2017). Proteins encoded by FLT3 (rs2481955) stimulates hematopoiesis and is 
reportedly expressed at high levels in a spectrum of hematologic malignancies, including 
AML. Mutations in FLT3 usually lead to a poor prognosis and is suggested to be a 
potential therapeutic target for kinase inhibitor (Gilliland and Griffin 2002). Similarly, 
PLCB1 (rs227130) is recently proposed as a potential therapeutic target for AML 
patients, since the monoallelic deletion or increased PLCB1 expression is a prognostic 
factor and is reportedly linked to the transition from myelodysplastic syndromes (MDS) to 
AML (Ratti et al. 2018; Damm et al. 2010; Fiume et al. 2014). 
 
These genes and their functional interpretation seem to explain potential underlying 
mechanisms; however, they by no means explain the actual biological functions nor do 
they provide a full picture of the genetic interactions in AML or acute GVHD. The SNPs 
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used in this study are common polymorphisms (MAF>0.005), and the locations are much 
sparser than the whole genome sequences. Thus, the representation of genes from the 
SNPs is merely a remote approximation. The highly ranked SNPs are not necessarily 
directly involved in the pathways linked to the disease; instead, some ungenotyped 
genes that share a high linkage disequilibrium with those SNPs may exert more 
significant influence on the disease status. On the other hand, the feature interactions 
captured through iRBA-RF suggest the statistical epistasis among these features or 
SNPs but not the biological epistasis. Therefore, functional interpretation from SNP sets 
needs much careful consideration. More rigorous experiments may be needed to 
validate the potential genetic interactions. Overall, it is a promising start to investigate 
the genetic interactions in transplant-related outcome studies while considering both 
donor’s and recipient’s genomes simultaneously.  
 
One of the advantages of using GIFI and PEFI-ranked features in RF is that it removes 
the arbitrariness of choosing the number of features. Positive values of GIFI or PEFI 
indicate the features contribute positively to the predictive power of the predictive models 
and a value of zero is an appropriate cutoff. The p-values of GIFI scores add additional 
confidence level to the selection, as do the confidence intervals to the PEFI scores. On 
the other hand, GIFI ranking and PEFI ranking are not always consistent with each 
other, as they are using two different criteria to measure the feature importance. 
Moreover, as many researchers have point out (Amrhein, Korner-Nievergelt, and Roth 
2017; Wellek 2017), a p-value is not a reliable metric to infer the significance, since it 
depends on assumptions of the models and the sample size and lacks reproducibility. Lu 
et al. (M. Lu and Ishwaran 2018) proposed standard error and confidence intervals of 
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PEFI as an alternative to the p-values of regression models and demonstrated the 
robustness of PEFI to the sample size and model assumptions. Especially, when the 
sample size is small, it is a more reliable indicator than p-values. Therefore, it is 
desirable to use the PEFI ranked feature set for further downstream analysis. 
 
There are several parameters to determine for the iRBA-RF model. The first step of 
feature elimination using iRBA requires four parameters: the optimal subset size (Ns), 
the number of iterations (Iteration), the percentage of features that will be removed after 
each iteration (pct), and the number of features to keep after the last iteration (featNum). 
The original VLSReliefF algorithm suggested a large sample size and relatively small Ns 
achieve reliable results (Eppstein and Haake 2008). By default, top 50th percentile 
(pct=0.5) rank of SNPs is selected after each iteration. However, in our experiment, this 
removes many interactive and relevant variables, and the final feature sets have very 
little predictive power. The goal of iRBA is to remove as many irrelevant variants as 
possible while keeping all possible interacting ones. In this study, we chose the following 
parameters for both scenarios: Ns=1000, Iteration=5, pct=0.25. As for featNum, we 
employed a grid search strategy to find the optimum values for each of the scenarios. As 
shown in Figure 4.8, featNum=200 for Scenario 1 and featNum=400 for Scenario 2 
achieved the best classification performance, measured by the normalized Brier score, 
AUC and overall OOB error rate. As for RF models, each forest has 300 trees 
(ntree=300) with the default mtry=sqrt(#dimensions). 
 
One caveat of the iRBA-RF model is that, unlike regression or a simple associations test, 
it cannot tell the direction of a variable’s impact on the disease (positive or negative,  
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                   (a) AML case-control scenario                                   (b) Acute GVHD scenario 
Figure 4.8 The effect of the number of SNPs. from 10,000, 5000, 1000, 900, 700, 500, 300, 200, 
100: the OOB prediction error reaches its minimum between 300 and 500 SNPs for both AML 
and acute GVHD. Number of features are shown on a log10 scale. OOB: Out-of-bag sample 
average prediction error, shown in percentage (%); AUC: Area under the ROC; Brier: the 
normalized Brier score. The optimal feature size would produce the minimum OOB error rate (%), 
the minimum Brier score and the maximum AUC value.  
protective or progressive) from the model. However, this may avoid or minimize the 
effect of Simpson’s paradox, where the positive or negative association of variables 
reverse sign due to the change of a confounding factor. Simpson’s paradox is a common 
issue in association studies, especially in a high-dimensional bioinformatics data set 
(Freitas 2019). Keep in mind that, the selected features collectively contribute to the 
predictive power and thus it is not an indication of the influence of a single SNPs on the 
disease. It is worth noting that the importance scores and feature ranking are a relative 
concept, and they have little indication of biological importance. In summary, the iRBA-
RF model offers a computationally efficient and functionally effective method to find the 
candidate variable groups whose interactions may exert to the disease status. With a 
larger cohort size with broader genomic coverage, it may effectively find the genetic 
interaction networks that are directly linked to the disease development.  
 93 
Conclusion 
We developed a hybrid feature selection model, iRBA-RF, to reduce the feature space 
and ultimately rank and select the variants that may be linked to the diseases in 
question, AML, and acute GVHD. The proposed model successfully selected the most 
related SNPs out of over 600 K and 1 M SNPs and produced a reasonable predictive 
accuracy. The model was applied to genomic data in this study, but it can be extended 
to examine multi-omics data with other clinical characteristics, as well as the multi-class 
prediction problems.  
 
As discussed above, evidence of the genes can be found in the literature to be linked to 
the disease in question; however, in order to determine their biological role and further 
assist optimized donor selection process and personalized therapeutic development, 
experiments on a larger cohort size, along with immunological wet lab validation 
experiments on the selected genes, are desired. 
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Chapter 5 Discussions and Conclusion 
Allo-HCT is a curative option for many hematologic malignancies and inherited or 
acquired genetic disorders, yet side effects limit its broader application. GVHD remains a 
principal barrier to more effective treatment, and immune responses that contribute to 
therapeutic benefit and adverse events are physiologically coupled. As personalized 
therapeutic treatment options advance, it is essential to precisely identify genetic factors 
that affect clinical outcomes, either protectively or aggressively. 
 
In this dissertation, we focused on acute GVHD after 10/10 HLA matched (HLA-A, -B, -
C, -DRB1, and -DQB1) allo-HCT from a genomic perspective. MHC genes are the most 
polymorphic known genes known and HLA matching is one of the most critical factors in 
the process of optimal graft selection. Here, we showed the sequence diversity of the 
classical HLA genes that are used in current clinical settings and provided evidence of 
high sequence variations outside the ARD exons. Despite the relatively large number of 
HLA matched donor-recipient pairs with their full-length classical HLA gene sequences, 
the current study cohort was not able to provide statistically significant results to support 
transplant outcome associations of non-ARD region mismatches. However, due to the 
low frequency of amino acid mismatches in the non-ARD region and their reportedly 
weak alloimmune reactions, we suggest that the non-ARD sequence mismatches within 
the ARD-matched DR pairs have limited influence on the development of post-transplant 
complications, such as acute GVHD, and may not be a primary factor. Meanwhile, the 
HLA gene haplotype mismatches and their clinical association is another interesting area 
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to investigate, as many studies have shown evidence of better outcomes in HLA 
haploidentical allo-HCT.  
 
Like many other common complex diseases, acute GVHD and other transplant-related 
complications involve many other genes. We first investigated the missense variant 
mismatches between donor and recipient from the whole genome sequences to identify 
genes that encode MiHAs. The clinical outcome study on the identified autosomal MiHAs 
found no statistically significant association with acute GVHD outcome, which may 
suggest that MHC mismatching outweighs other genetic mismatches as contributors to 
acute GVHD risk. More carefully stratified studies may be needed to confirm each 
specific MiHA cases; however, such randomized case studies are a big challenge in allo-
HCT since the transplant cases each year are limited and each case is almost unique. 
On the other hand, we were able to identify multiple MiHAs encoded by genes from the 
Y chromosome that show statistically significant association with acute GVHD. Our 
limited study cohort of primarily ethnic Caucasians suggests that Y chromosome 
haplotypes in this population increase the risk of acute GVHD for male patients when 
paired with HLA matching female donors. This provides genetic evidence to support the 
clinical preferences of HLA-matched male donors over female donors with the same 
condition for male patients. For further genomics investigations with a more extensive 
and diverse cohort, we recommend controlling for confounding factors such as HLA-
DPB1 T-cell epitope permissibility and tissue-specific gene expression.  
 
One of the challenges in transplant genomic studies is the ultra-high dimensional 
genomic data from both donors and recipients. Here we developed a hybrid feature 
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selection model, iRBA-RF, to provide a bioinformatics data mining tool for such 
investigations and clinical outcome studies. The proposed iRBA-RF model successfully 
selected the most related SNPs that have evidence to be linked to the diseases in 
question, out of over 600 K and 1 M SNPs, and produced a reasonable predictive 
accuracy. The model may be extended to investigating multi-omics data (epigenomics, 
proteomics, microbiome, and metabolomics) with other clinical characteristics, as well as 
the multi-class prediction problems, which would be the future work to assess. Genetic 
factor discovery in silico may provide insightful interpretation of biological pathways; 
however, the clinical implications need further assessment and validation through 
immunological wet lab experiments.  
 
In summary, this work offers evidence and guidance for further research in acute GVHD 
and allo-HCT and provides useful bioinformatics and data mining tools for transplant 
genomic studies, and can be extended to broader investigations including epigenetics in 
acute GVHD, pre-transplantation screening of potential donors, biomarker discovery and 
risk assessment of transplant outcomes.  
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Appendix 
A.1 Supplementary tables and figures for Chapter 3 
[Supplementary Table 3.1.xlsx] 
Autosomal MiHAs do not associate with acute GVHD. Each row represents a single 
MiHA present in the whole genome sequencing (WGS) or microarray cohort (or both) 
with characterized restricted HLA allele, encoding single nucleotide polymorphism 
(SNP), gene, and counts in acute GVHD and non-GVHD groups. P-values were 
calculated, and multiple hypotheses corrected for, as described in Methods. MAF – 
minor allele frequency. 
 
Supplementary Figure 3.1: A Venn diagram shows individual counts in overlapping 
categories for donor-recipient pairs that were retrospectively matched at HLA-DPB1 by 
allele, T-cell epitope permissibility (TCE), expression, and functional distance.  
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Supplementary Figure 3.2: A genomic annotation workflow to identify known and novel 
outcomes-associated variants. Raw sequence data were processed as described 
(Methods) to generate a single binary alignment (BAM) and variant call format (VCF) file 
per sample. Comparative analysis of donor-recipient pairs resulted in a single VCF file 
containing patient-specific variants, which were annotated further. Male recipients with 
female donors were treated separately to analyze variants on the Y chromosome. 
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Supplementary Figure 3.3: Tissue-specific gene expression for PCDH11Y (A), USP9Y 
(B), UTY (C), and NLGN4Y (D).  
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A.2 Supplementary materials for Chapter 4  
Supplementary tables 4.1-4.4 
[Supplementary tables Chapter 4.xlsx] 
 
Supplementary Table 4.1 Top ranking SNPs from GIFI for Scenario 1: AML case-control 
Supplementary Table 4.2 Top ranking SNPs from PEFI for Scenario 1: AML case-control  
Supplementary Table 4.3 Top ranking SNPs from GIFI for Scenario 2: acute GVHD 
case-control 
Supplementary Table 4.4 Top ranking SNPs from PEFI for Scenario 2: acute GVHD 
case-control  
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Supplementary Table 4.5. Characteristics of acute myeloid leukemia 
patients transplant cases 
 
Variable Value 
No. of transplant cases 
No. of transplant centers 
Recipient age, median (range), years 
Age at transplant, yr 
<20  
20-59 
≥60  
Recipient race group 
CAU  
AFA  
API  
HIS  
Native American  
Other/multiple/declined/unknown 
Donor age, yrs 
18-29  
30-39 
40-49  
≥50 
Donor race group 
CAU  
AFA  
API  
HIS  
Native American  
Other/multiple/declined/unknown 
AML disease status at transplant 
Early 
Intermediate 
Advanced 
Other 
Graft Type 
Bone marrow  
Peripheral blood 
In vivo T cell depletion 
No  
Yes  
ATG given 
No 
Yes 
Donor/recipient CMV match 
Negative/negative  
Negative/positive  
Positive/negative 
Positive/positive  
331 
97 
42 (0~65 yrs) 
 
42     (12.7%) 
276   (83.4%) 
13     (3.9%) 
 
319   (96.4%) 
2       (0.6%) 
8       (2.4%) 
0       (0 %) 
1       (0.3%) 
1       (0.3%) 
 
152   (45.9%) 
89     (26.8%) 
71     (21.5%) 
19     (5.7%) 
 
284   (85.8%) 
3       (0.9%) 
9       (2.7%) 
0       (0 %) 
0       (0 %) 
35     (10.6%) 
 
243   (73.4%) 
10     (3.0%) 
77     (23.3%) 
1       (0.3%) 
 
132   (39.9%) 
199   (60.1%) 
 
238   (71.9%) 
93     (28.1%) 
 
243   (73.4%) 
88     (26.6%) 
 
107   (32.3%) 
114   (34.4%) 
33     (10.0%) 
69     (20.9%) 
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Unknown 
GVHD prophylaxis 
Ex vivo T cell depletion  
CD34 Selection 
Cyclophosphamide  
Tacrolimus + (MTX or MMF) ± other  
Tacrolimus ± other  
Tacrolimus alone  
CsA + (MMF or MTX) ± other (except 
Tacrolimus) 
CsA ± other (no MTX nor MMF)  
CsA alone  
Other  
HLA-DPB1 typing 
Double mismatch  
Single mismatch 
Matched 
Missing/not typed 
Donor/recipient sex match 
Male/male  
Male/female  
Female/male  
Female/female 
GVHD outcome 
Grades 0~I acute GVHD 
Grades II~IV acute GVHD 
8       (2.4%) 
 
20     (6.0%) 
0       (0%) 
5       (1.5%) 
206   (62.2%) 
15     (4.5%) 
4       (1.2%) 
74     (22.4%) 
2       (0.6%) 
3       (0.9%) 
2       (0.6%) 
 
58     (17.5%) 
115   (34.7%) 
31     (9.4%) 
127   (38.4%) 
 
127   (38.4%) 
97     (29.3%) 
40     (12.1%) 
67     (20.2%) 
 
185   (55.9%) 
146   (44.1%) 
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Supplementary Table 4.6. HLA typing summaries 
 
HLA-A  Freq  HLA-B Freq  HLA-C Freq 
A*02:01 
A*01:01 
A*03:01 
A*24:02 
A*11:01 
A*29:02 
A*68:01 
A*26:01 
A*32:01 
A*31:01 
A*25:01 
A*23:01 
A*30:01 
A*33:01 
A*68:02 
A*02:05 
A*30:02 
A*03:02 
A*24:03 
A*24:17 
A*30:04 
A*36:01 
174 
115 
94 
50 
32 
21 
21 
18 
17 
15 
13 
12 
12 
6 
6 
3 
3 
2 
1 
1 
1 
1 
 B*07:02 
B*08:01 
B*44:02 
B*40:01 
B*15:01 
B*35:01 
B*18:01 
B*27:05 
B*13:02 
B*44:03 
B*57:01 
B*14:02 
B*38:01 
B*37:01 
B*52:01 
B*49:01 
B*51:01 
B*55:01 
B*56:01 
B*14:01 
B*40:02 
B*35:03 
B*39:01 
B*41:01 
B*45:01 
B*50:01 
B*15:17 
B*27:02 
B*35:02 
B*47:01 
B*53:01 
B*58:01 
B*15:02 
B*15:03 
B*15:10 
B*15:18 
B*35:08 
B*58:02 
114 
107 
73 
41 
40 
37 
36 
21 
19 
19 
16 
15 
13 
11 
8 
7 
6 
6 
6 
5 
5 
3 
3 
3 
3 
3 
2 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
 C*07:01 
C*07:02 
C*05:01 
C*03:04 
C*06:02 
C*04:01 
C*03:03 
C*12:03 
C*08:02 
C*01:02 
C*02:02 
C*16:01 
C*07:04 
C*12:02 
C*14:02 
C*17:01 
C*02:10 
C*08:01 
C*15:02 
126 
115 
71 
56 
56 
54 
29 
26 
20 
19 
16 
12 
10 
8 
3 
2 
1 
1 
1 
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HLA-DRB1 Freq  HLA-DQB1 Freq 
DRB1*15:01 
DRB1*03:01 
DRB1*07:01 
DRB1*01:01 
DRB1*04:01 
DRB1*13:01 
DRB1*11:01 
DRB1*13:02 
DRB1*04:04 
DRB1*08:01 
DRB1*11:04 
DRB1*12:01 
DRB1*01:02 
DRB1*14:01 
DRB1*01:03 
DRB1*15:02 
DRB1*04:02 
DRB1*09:01 
DRB1*13:03 
DRB1*04:07 
DRB1*10:01 
DRB1*16:01 
DRB1*04:03 
DRB1*04:05 
DRB1*11:03 
DRB1*08:02 
DRB1*08:04 
DRB1*11:02 
DRB1*12:02 
DRB1*13:04 
DRB1*13:05 
DRB1*14:02 
DRB1*16:02 
116 
105 
74 
60 
56 
37 
30 
24 
23 
13 
12 
12 
11 
11 
10 
8 
4 
4 
4 
3 
3 
3 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
 DQB1*06:02 
DQB1*02:01 
DQB1*03:01 
DQB1*05:01 
DQB1*02:02 
DQB1*03:02 
DQB1*06:03 
DQB1*06:04 
DQB1*03:03 
DQB1*04:02 
DQB1*05:03 
DQB1*06:01 
DQB1*05:02 
DQB1*06:09 
116 
106 
103 
77 
59 
48 
37 
21 
18 
15 
11 
8 
4 
3 
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Supplementary Material 4.7: Microarray genotype data preprocessing 
 
The original SNP genotype data was obtained and processed by Madbouly et al. and 
described in (Madbouly et al. 2017). In this study, we performed the quality control 
separately and did not use the imputed genotypes.  
 
We have removed individuals that show ambiguous sex genotype than their reported 
sex. The rest of parameters used in the SNP filtering is as follows. 1) If a SNP minor 
allele frequency (MAF) is less than 0.005 or showed up in less than 10 individuals, then 
those SNPs are filtered out. 2) SNPs that have less than 95% call rate are removed. 3) It 
is recommended to use the control-only samples for Hardy-Weinberg equilibrium (HWE) 
test (Anderson et al. 2010). Here we used the healthy donor-only samples and excluded 
the SNPs that have P-values lower than 0.001 after the HWE test. After these steps, we 
obtained 630,793 SNPs for the 331 donor-recipient pairs.  
 
 
 
 
